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ABSTRACT 
Non-small cell lung cancer (NSCLC) is the most common type of lung cancer, which is the 
leading cause of cancer death, with an increasing prevalence every year. Specific treatments 
for some of the multiple kinds of NSCLC have been developed, but their efficacy is low and 
they are not applicable to all types. Cell viability experiments suggested that rice bran oil 
could be a source of anti-carcinogenic phytochemicals against NSCLC. γ-Oryzanol is the 
major component in rice bran oil and has anti-cancer properties on various prostate cancer 
cell lines and in some animal models. The goal of this study was to determine whether the 
most abundant components in the γ-oryzanol mixture (24-mCAF, CAF, CMF and β-SF) have 
cytotoxic activity against A549 cells, a NSCLC cell line. 
The effect of these compounds on cell proliferation was tested using the colorimetric 
methylthiazol tetrazolium (MTT) assay. Among all four compounds, 24-mCAF showed the 
strongest inhibitory effect on cell proliferation of A549 cells, while β-SF did not seem to 
affect it. 
An iTRAQ-based quantitative proteomics analysis combined with Ingenuity Pathway 
Analysis (IPA) revealed that the changes in the proteome caused by 24-mCAF were 
consistent with cancer inhibition. Cell death and apoptosis were activated and cell 
proliferation was inactivated. Myb binding protein 1A is a tumor suppressor protein that 
binds to several transcription factors. The results obtained in this study indicate that 24-
mCAF induces MYBBP1A up-regulation, which contributes to stop cancer progression 
through different mechanisms. These mechanisms include its interaction with P53, which 
induces apoptosis and cell cycle arrest; its interaction with NFкB, which inhibits 
inflammatory processes; and its interaction with SIRT6, which regulates the expression of 
several cancer-related proteins. Up-regulation of MYBBP1A by 24-mCAF was verified with 
western blot and the results were consistent with those obtained with iTRAQ. This study 
provides the first step for understanding the effect of γ-oryzanol on A459 cells at the cellular 
and molecular level, providing a possible candidate for NSCLC treatment or prevention.  
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CHAPTER I. INTRODUCTION 
1.1. Lung cancer 
Lung cancer is by far the leading cause of cancer death in both men and women. In 2016, 
lung and bronchus cancer are expected to cause 27% of the cancer deaths in males and 26% 
in women in the United States. It is the second most commonly diagnosed cancer, accounting 
for 14% of the new cases. The prevalence of this type of cancer keeps increasing worldwide 
each year (American Cancer Society, 2016; Jemal et al., 2009).  
Non-small cell lung cancer (NSCLC) is the most common type of lung cancer, representing 
about 85% of the cases. The two most commonly mutated oncogenes in NSCLC are the 
epidermal growth factor receptor (EGFR) and Kirsten rat sarcoma (KRAS). Mutations in 
these two genes are mutually exclusive in NSCLC. When EGFR is overexpressed, it causes 
cells to grow in a faster and uncontrolled way (Figure 1). Erlotinib and gefitinib are 
epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) that block the 
signal from the overexpressed EGFR and that are used as a treatment for NSCLC. KRAS 
encodes a GTPase downstream of EGFR which signals through the PI3K/AKT/mTOR and 
STAT pathways involved in cell survival, and the RAS/ RAF/MEK/MAPK pathway involved 
in cell proliferation; its mutation also results in uncontrolled growth. Cells presenting KRAS 
mutations are not sensitive to treatment with TKIs like the drugs mentioned above. General 
cancer treatments, such as surgery, chemotherapy and radiotherapy, are usually applied to 
NSCLC patients with KRAS mutations, since there is no targeted therapy available (Krypuy et 
al., 2006; Riely et al., 2009). 
 
Figure 1. Simplified schematic of EGFR and KRAS signaling pathways. Adapted from Riely et al., 2009. 
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KRAS mutations occur in approximately 33% of NSCLCs and the prognosis of this type of 
cancer is very poor. KRAS is one of the most difficult drug targets due to its picomolar 
affinity for GTP/GDP and the absence of known allosteric regulatory sites. When it is 
mutated GTP hydrolysis is impaired, which results in the increase of the proportion of active 
GTP-bound KRAS. Although some KRAS inhibitors have been reported in the past few 
years, the design of a drug remains a big challenge. There is a great need for the development 
and implementation of a novel, effective and affordable treatment for this kind of cancer 
(Ostrem et al., 2013).  
1.2. Rice bran oil as a source of anti-carcinogenic phytochemicals. 
Plant extracts have been widely used in traditional medicine for centuries. Nowadays, the use 
of bioactive phytochemicals is gaining attention due to their low cost, low toxicity, high 
tolerability and reported biological activities. Several phytochemicals, such as reservatrol, 
curcumin, capsaicin and genistein have been associated with anti-carcinogenic activity and 
protective role against side effects of conventional chemotherapeutic agents (Pal et al., 2016; 
Goyal et al., 2016). 
Rice bran oil is an important byproduct of rice milling industry that is gaining commercial 
importance because of its health benefits. Although rice bran oil has a similar fatty acid 
profile than other oils, it contains hundreds of bioactive compounds that are responsible for 
its antioxidant activity, cholesterol lowering capacity and anti-cancer effects (Sohail et al., 
2016). These properties have been extensively studied during the last years. Dapar et al., 
(2013) showed that the bran oil from IR64 rice has cytotoxic activity against A549 lung 
adenocarcinoma epithelial cells, a NSCLC cell line that carries KRAS mutations. This 
finding suggests that some of the bioactive phytochemicals from rice bran oil might be good 
candidates for prevention or treatment of NSCLC. 
1.3. Composition of rice bran oil 
Rice bran constitutes 6% of a rice kernel and includes pericarp, seed coat, nucellus, aleurone 
and soft germ of a rice seed (Figure 1). Approximately 15-20% of the bran is oil and around 
4% of this oil is unsaponifiable material, which is a relatively large proportion compared to 
other vegetable oils. The unsaponifiable material is mainly constituted by γ-oryzanol (1-3% 
w/w) and vitamin E derivatives (tocopherols and tocotrienols). γ-Oryzanol is the bioactive 
component of rice bran oil that has shown the most beneficial properties. It was initially 
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thought to be a single component, but it is actually a complex mixture of different ferulate 
esters of triterpene alcohols and plant sterols. 24-methylenecyloartanyl ferulate (24-mCAF), 
cycloartenyl ferulate (CAF), campesteryl ferulate (CMF) and β-sitosteryl ferulate (β-SF) are 
the most abundant compounds in γ-oryzanol, contributing to about 94% of the total mass 
(Table1; Figure 2) (Patel et al., 2004; Britz et al., 2007; Kim et al., 2015). 
 
 
Figure 2. Rice kernel structure adapted from Huang et al., 2003. 
 
 
Table 1. Most represented compounds in γ-oryzanol 
Name Abbreviation % of total mass 
24-methylenecycloartanyl ferulate 24-mCAF 23 - 42 
Cycloartenyl ferulate CAF 10 - 41 
Campesteryl ferulate CMF 8 – 20 
β-sitosteryl ferulate β-SF 7 - 14 
Kim et al., 2013 
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Figure 3. Structure of the most represented compounds in γ-oryzanol. Kim et al., 2015. 
 
1.4. Beneficial properties of γ-oryzanol 
Numerous studies have reported the beneficial properties of γ-oryzanol, which was first 
known as an antioxidant compound. Xu et al. (2001) used accelerated oxidation of linoleic 
acid to test the antioxidant activity of 24-mCAF, CAF and CMF. Linoleic acid is easily 
oxidized because it contains 1,4-pentadiene, which is very vulnerable to free radical attack. 
Its oxidation can be determined by measuring the production of linoleic acid hydroperoxides. 
All three compounds significantly reduced the rate of hydroperoxides production. Their 
results suggest that the antioxidant activity of these compounds come from the ferulate 
portion of the molecule, since the proportions of different linoleic acid hydroperoxides 
obtained with each of the three components are similar to the one obtained with ferulic acid 
(Xu et al., 2001). 
Another important property of γ-oryzanol is its cholesterol lowering capacity. Several studies 
on humans and animals showed that γ-oryzanol lowers low density lipoprotein and serum 
total cholesterol levels by influencing absorption of dietary cholesterol in the intestine. 
During digestion, steryl ferulates are thought to be cleaved into ferulic acid and free sterols 
by intestinal enzymes. The released free sterols inhibit the absorption of cholesterol into the 
systemic circulation (Mandak et al., 2004). 
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γ-Oryzanol also possesses anti-inflammatory activity mainly due to NF-κB inhibition. 
Inflammatory responses typically require NF-κB translocation into the nucleus. Sakai et al. 
(2012) studied the effect of γ-oryzanol in NF-κB translocation in bovine aortic endothelial 
cells (BAECs) and found that a treatment of 30 µM for 16 hours considerably inhibited the 
translocation. The inhibitory effect of γ-oryzanol was higher than the observed with 
pyrrolidine dithiocarbamate (PDTC), a synthetic antioxidant known as a NF-κB inhibitor, at 
the same concentration.  
The synthesis and release of dopamine and norepinephrine in the medial basal hypothalamic 
region of the rat brain were increased by γ-oryzanol. These molecules are hypothalamic 
neurotransmitters that influence the synthesis and release of hormones in the pituitary 
(Wheeler et al. 1991). Treatment with 300 mg of γ-oryzanol administered orally produced a 
significant reduction of the elevated serum thyroid-stimulating hormone levels produced by 
the pituitary in hypothyroid patients (Patel et al., 2004). An intravenous injection of 5 mg γ-
oryzanol to male rats remarkably decreased the levels of luteinizing hormone released by the 
pituitary. This effect might be beneficial in the management of menopause symptoms 
(Wheeler et al., 1991). 
Several studies have reported the anti-cancer properties of γ-oryzanol. Klongpityapong et al. 
(2013) showed that γ-oryzanol significantly inhibits cell growth on the prostate cancer cell 
lines DU145 and PC3, and that it down-regulates the expression of the catalase and 
glutathione peroxidase genes. These genes are both important in protecting the cell from 
oxidative damage and their down-regulation can lead to cell death. Hirsch et al. (2015) 
reported that this compound decreases cell viability by activating apoptosis and blocking cell 
cycle progression at G2/M in PC3 cells and at G0/G1 in DU145 cells. In addition, they found 
that genes CAV-1, important for cell proliferation, and PCGEM1, involved in apoptosis 
inhibition, were down-regulated after treatment with γ-oryzanol in PC3 and DU145 cells, 
respectively. Kim et al. (2012) investigated the effect of γ-oryzanol and other rice bran oil 
components on tumor growth in mice. After administering the compounds in the diet for 2 
weeks, animals were inoculated with CT-26 colon cancer cells and they were treated for 2 
more weeks. Tumors from animals treated with γ-oryzanol showed significantly less growth 
than tumors from the control mice. Tumor inhibition was associated with increased cytolytic 
activity of splenic natural killer cells, partial restoration of nitric oxide production and 
phagocytosis in peritoneal macrophages, increased levels of pro-inflammatory cytokines 
released from macrophages, reduced number of blood vessels inside the tumor, and reduction 
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of the expression of vascular endothelial growth factor (VEGF), cyclooxy-genase-2 (COX-2) 
and 5-lipoxygenase-5 (5-LOX). These findings suggest that γ-oryzanol may inhibit 
neoangiogenesis inside the tumors (Szcześniak et al., 2015).  
1.5. Absorption and metabolism of γ-oryzanol 
The absorption of plant sterols is generally limited; approximately only 5% of ingested plant 
sterols are absorbed. Fujiwara et al. (1983) administered γ-oryzanol-14C orally to rats and 
found that, after 72 hours, 9.8% radioactivity was found in the urine and 84.5% in the feces, 
which indicates that absorption of γ-oryzanol was very poor (Huang et al., 2003). 
Huang et al. (2003) studied the digestibility of γ-oryzanol using an in vitro model that 
includes pepsin, bile and pancreatin (a mixture of pancreatic enzymes containing lipase, 
amylase, protease, cholesterol esterase and other enzymes) solutions. They tested the effect of 
these enzymes on γ-oryzanol in crystalline and micellar form. Their results show that γ-
oryzanol concentration decreases after peptic and pancreatic digestion, especially when it is 
in micellar form, probably because when it is in crystalline form it is less accessible for the 
enzymes. CMF and β-SF decreased more obviously than other γ-oryzanols after incubation 
with pancreatic enzymes, which indicates that they may be more susceptible to digestion. 
This may be due to the similarity of their chemical structure with cholesterol (Figure 3). 
Unlike other γ-oryzanols, they do not have methyl groups in their ring structures and the side 
chains have only an extra methyl group difference at C-24 position for CMF and an extra 
ethyl group for β-SF in comparison with cholesterol. Further analysis of the digestion 
products of γ-oryzanol with GC/MS revealed that the amount of free sterols increased, 
supporting the hypothesis that γ-oryzanols are hydrolyzed by pancreatic enzymes at the ester 
bond, releasing free sterols and ferulic acid. However, ferulic acid was not detected, which 
suggests that it is further degraded (Huang et al., 2003).  
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Figure 4. Chemical structures of cholesterol, campesteryl ferulate and sitosteryl ferulate 
 
 
1.6. Toxicity of γ-oryzanol 
Toxicity of γ-oryzanol has been tested in different organisms. Induction of carcinogenesis in 
mice was studied by administering 2 g/kg body weight/day γ-oryzanol in the diet of B6C3F1 
mice for 78 weeks. Tumor incidence seemed not to be different between the control and 
treated animals, indicating that γ-oryzanol is not toxic for B6C3F1 mice (Huang et al., 2003). 
Additionally, Sakai et al. (2012) tested the cytotoxic effect of γ-oryzanol on bovine aortic 
endothelial cells (BAECs). After treatment with 30 µM γ-oryzanol for 24 hours, no influence 
in the percentage of viable cells compared to vehicle-treated cells was observed.  
Moreover, only negative results were obtained when the mutagenic effect of γ-oryzanol was 
investigated using the Bacillus subtilis Rec assay (bacterial DNA repair test), Ames test 
(bacterial reverse mutation test), rat bone marrow chromosome aberration test, and metabolic 
cooperation inhibition test using Chinese hamster V79 cell. 
In contrast to the results mentioned above, Hirose et al. (1998) reported carcinogenesis 
enhancing effect of γ-oryzanol on the lungs of F344 rats. However, this effect was weak and 
occurred only at very high dose. Animals were treated with 3 different carcinogens (2,20-
dihydroxy-di-n-propyl- nitrosamine (DHPN), N-ethyl-N-hydroxyethyl-nitrosamine (EHEN) 
and 3,20-dimethyl-4-aminobiphenyl (DMAB)) for 3 weeks and then were treated with γ-
oryzanol in their basal diet for 32 weeks. Increase in the multiplicity of lung tumors was 
observed at a dose of 1% γ-oryzanol, but not at lower doses.  
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1.7. γ- Oryzanol and non-small cell lung cancer: Hypotheses and objectives 
The reported cytotoxic activity of rice bran oil in A549 cells makes it an interesting target in 
the search for anti-carcinogenic phytochemicals. The evidence that γ-oryzanol, the major 
component of rice bran oil, has anti-cancer effects on other types of cancer raises the question 
of whether γ-oryzanol has cytotoxic effects on NSCLC. γ-Oryzanol is not a single compound, 
but a mixture of steryl ferulates where 24-mCAF, CAF, CMF and β-SF are the most abundant 
ones, which leads to the question of what are the bioactive compounds in this mixture. The 
purpose of this study was to answer these questions by analyzing whether 24-mCAF, CAF, 
CMF and β-SF (γ-oryzanols) have anti-cancer activity against NSCLC and, if so, what are 
their mechanisms of action. 
The first objective of this study was to test the effect of γ-oryzanols on A549 cells viability 
using a methylthiazol tetrazolium (MTT) assay (Table 2.1). This colorimetric assay uses a 
tetrazolium dye (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) that, when it 
is reduced by the mitochondrial NAD(P)H oxidoreductases, turns into an insoluble purple 
formazan. This formazan can be dissolved using dimethyl sulfoxide (DMSO) and the 
absorbance of the resulting solution reflects the number of viable cells (Mosmann et al., 
1983). Cell viability was expected to be affected by some γ-oryzanols, but not necessarily by 
all of them. 
As a second objective, a quantitative proteomics approach was taken to understand the 
molecular changes caused by γ-oryzanols on A549 cells. Isobaric tags for relative and 
absolute quantification (iTRAQ) were used to quantify changes in protein expression (Table 
2.2). These tags have identical overall mass, but there are 8 versions that vary in terms of the 
distribution of the heavy carbon and nitrogen isotopes within their structure. They are formed 
by a peptide reactive group, a balance group and a reporter group (Figure 5). The peptide 
reactive group labels peptides through free amine groups in the N-termini and lysine side 
chains. When a labeled peptide is fragmented, the reporter ions are released. The intensity of 
the signals of the reporter ions allows for calculating the relative abundance of peptides 
(Unwinn et al., 2010). γ-Oryzanols were expected to affect the expression of proteins 
involved in the regulation of apoptosis and cell cycle progression, as they have shown to do 
in prostate cancer cells. 
In order to validate the results obtained, the third objective of this study was to analyze the 
expression changes of proteins of interest using a different technique (Table 2.3). Western 
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blot was chosen as a validation method. Together, these experiments allowed determining the 
effect of γ-oryzanol on NSCLC at the cellular and molecular level, providing a possible 
candidate for NSCLC treatment or prevention. 
 
Figure 5. Structure of iTRAQ labels 
 
 
Table 2. Summary of objectives, methodology and specific hypotheses 
2.1 Objective 1 Effect of γ-oryzanols on cell 
viability of A549 cells 
Hypothesis: γ-Oryzanols inhibit cell 
viability of A549 cells. 
Methods: MTT assay 
2.2 Objective 2 Quantification of the 
changes in protein 
expression in response to γ-
oryzanols 
Hypothesis: γ-Oryzanols affect the 
expression of proteins involved in 
apoptosis and cell cycle progression. 
Methods: iTRAQ, SCX, LC-MS/MS, 
IPA 
2.3 Objective 3 Validation of results Hypothesis: Expression changes of 
proteins of interest are consistent 
using different methods. 
Methods: Western Blot 
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CHAPTER 2. METHODOLOGY 
2.1. Cell culture 
A549 human adenocarcinoma epithelial cells were obtained from the American Type Culture 
Collection (ATCC). Cells were cultured in Dulbecco’s Modified Eagle Medium (DMEM, 
high glucose, pyruvate) supplemented with 10% v/v fetal bovine serum (FBS), 100 U/mL 
penicillin and 100µg/mL streptomycin. From now on, this composition will be referred to as 
“complete DMEM”. Cells were grown at 37 ºC and 5% CO2.  
2.2. Cell viability assay 
Cells were seeded in 96-well plates at a concentration of 10
4
 cells per well in 100 µL of 
complete DMEM and incubated for 24 hours. They were starved with FBS-free medium for 
24 hours. γ-Oryzanols (24-mCAF, CAF, CMF and β-SF) were added in increasing 
concentrations (10, 25, 50 and 75 µM). DMSO was used as a carrier for γ-oryzanol; the final 
concentration of DMSO in each condition was 0.75% v/v. There were three biological 
replicates of each treatment. Cells were treated for 72 hours and they were then incubated 
with 200 µL of 500 µg/mL MTT for 4 hours. The supernatant was removed, 200 µL of 
DMSO were added and the optical density was read at 550 nm (OD550). 
2.3. Protein extraction 
Cells were plated in 75 cm
2
 culture flasks in complete DMEM. When they reached 
approximately 50% confluence, they were starved with 0.05% v/v FBS for 24 hours. Cells 
were treated with 50 µM 24-mCAF for 72 hours and a control culture was treated with 
DMSO (the total amount of DMSO in both conditions was 0.5% v/v. Four biological 
replicates of each condition were used. After 72 hours of treatment, cells were harvested 
using a cell scraper and washed 3 times with phosphate buffered saline (PBS), centrifuging at 
2,000 rpm for 10 minutes each time. Pellets were resuspended in 0.5 mL lysis buffer (10 mM 
Tris, pH 7.4, 100 mM NaCl, 1 mM EDTA, 2 mM Na3VO4, 1 mM EGTA, 1 mM NaF, 20 mM 
Na4P2O7, 1% v/v Triton X-100, 10% v/v glycerol, 0.1% v/v SDS, 0.5% v/v deoxycholate, 
Halt
TM
 protease inhibitor cocktail) and incubated for 30 minutes, mixing on a vortex every 10 
minutes. Lysates were then sonicated in ice using an ultrasonic cell disruptor for 15 seconds, 
3 times, waiting 2 minutes in between, and centrifuged for 10 minutes at 13,000 rpm and 4 ºC 
to. Supernatant was transferred to a clean tube.  
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Protein concentration was measured according to the Bradford method. Samples were diluted 
1:8 and 4 µL were mixed with 200 µL of Biorad Protein Assay Dye diluted 1:5 in a 96-well 
microtiter plate. Bovine serum albumin (BSA) was used as a calibrator. Absorbance was read 
at 595 nm. 
2.4. Buffer exchange and sample concentration 
To avoid the presence of components from the lysis buffer that could interfere with the 
iTRAQ labeling reaction, buffer was exchanged to 1 M TEAB pH 8.5 using an Amicon 
Ultra-0.5 mL 3K centrifugal filter. The sample was concentrated to 100 µL. 
2.5. Protein digestion 
One hundred micrograms of each sample (4 controls and 4 treated) were transferred to new 
tubes and volume was adjusted to 20 µL with TEAB buffer. Proteins were denatured and 
reduced using 0.05% v/v SDS and 5 mM tris(2-carboxyethyl)phosphine (TCEP) and 
incubating at 60 ºC for 1 hour. Cysteine residues were alkylated with 10 mM 
methylmethanethiosulfate (MMTS) for 10 minutes at room temperature. Proteins were 
digested by adding 5 µg of sequencing-grade modified porcine trypsin resuspended in water 
and incubating at 37 ºC for 14 hours. 
2.6. iTRAQ labeling 
iTRAQ-8plex reagents were resuspended in 50 µL of isopropanol, added to the samples and 
allowed to react for 2 hours at room temperature. Labels 113, 114, 115 and 119 were used on 
the control samples; labels 116, 117, 118 and 121 were used on the treated samples. After 
labeling, samples were pooled together and TEAB buffer was evaporated on a SpeedVac, 
adding water to avoid dryness. The sample was then resuspended in 100 µL SCX-A (7 mM 
KH2PO4, 30% ACN, pH 2.65) and pH was adjusted to < 2.65 using phosphoric acid.  
2.7. Sample fractionation - SCX chromatography 
Sample was fractionated using strong cation exchange chromatography (SCX) on an Agilent 
1100 high performance liquid chromatography (HPLC) system equipped with a diode array 
detector and with a polysulfoethyl aspartamide column (2.1 x 200 mm, 5 µm beads, 200 Å 
pore size). One hundred microliters of sample were injected and the flow rate was 0.2 
mL/min. Elution gradient was 5 minutes of 100% SCX-A, 0-30% SCX-B (7 mM KH2PO4, 
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30% ACN, 500 mM KCl, pH 2.65) in 10 min, 30-60% SCX-B in 20 min, 60-100% SCX-B in 
5 min, 100% SCX-B for 5 min and 100% SCX-A for 15 min. One-minute fractions were 
collected from 5 to 60 min after the start of the gradient. Fraction volume was reduced to 100 
µL in SpeedVac and fractions were desalted using 100 µL ZipTip C18 tips. 
2.8.  LC-MS/MS analysis 
A nanoAdvance UHPLC coupled to a maXis impact mass spectrometer equipped with a 
CaptiveSpray source (Bruker) and a Magic C18AQ reversed-phase, 0.1 x 150 mm, 3µm 
particles and 200 Å pore size analytical column was used. Elution was with a gradient from 
5% to 45% solvent B in 80 minutes at a flow rate of 500 nL/min. Solvent A was 0.1% v/v 
formic acid (FA), 5% v/v acetonitrile (ACN) and 95% v/v LC-MS-grade water. Solvent B 
was 0.1% v/v FA, 95% v/v ACN and 5% v/v water. Samples were measured in auto MS/MS 
mode, with a mass range of m/z 50-2200. Acquisition speed was 2 Hz in MS and 4 or 16 Hz 
in MS/MS mode depending on precursor intensity.  Precursors were selected in the m/z 300-
1221 and 1225-2200 range with charge states at 2-5 (singly charge ions were excluded). 
Active exclusion was activated after 1 spectrum for 2 minutes. 
2.9. Data analysis 
Peak list files in mascot generic file (mgf) format were generated using DataAnalysis 
software and submitted to ProteinScape (Bruker). Swissprot was used as a database for 
Mascot searches. The peptide and MS/MS tolerance were set to 50 ppm and 0.06 Da, 
respectively.  Two missed cleavages were allowed. Methylthio (C) and iTRAQ-8plex (K and 
N-term) were added as fixed modifications. Oxidation (M) and iTRAQ-8plex (Y) were added 
as variable modifications. Proteins with a score below 20 and peptides with a score below 15 
were discarded. 
Quantification ratios were obtained using WARP-LC (Bruker). In order to set up a cutoff 
ratio that will determine which proteins are up- and down-regulated, and also to identify 
proteins that were consistently expressed in the control samples, all ratio possibilities 
between the 4 controls were calculated (114/113, 115/113, 119/113, 115/114, 119/114 and 
115/119). Ratios were normalized dividing by the overall median. The logarithm of the 
median of all control normalized ratios was plotted against the mascot score for each protein 
(Figure 6). This plot helped to set up a cutoff of 1.25. Proteins inside this range are 
considered to be consistently expressed in the control samples; proteins outside of this range 
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are considered to have different expression in the different control samples and were not 
accepted for further analysis.  
 
Figure 6. Plot of the logarithm of the median of all possible control/control ratios against the Mascot score. 
Dashed red lines mark the ± 1.25-fold cutoff. Dots that fall inside the region marked by the lines represent 
proteins that are considered to be consistently expressed among the control samples and that were accepted for 
further analysis. Dots that fall outside the lines represent proteins which expression seems not to be consistent 
among the control samples and were not considered for further analysis. 
 
All combinations of treatment/control ratios were calculated for the accepted proteins 
(116/113, 117/113, 118/113, 121/113, 116/114, 117/114, 118/114, 121/114, 116/115, 
117/115, 118/115, 121/115, 116/119, 117/119, 118/119 and 121/119). Ratios were 
normalized dividing by the overall median. The median of all normalized ratios was 
calculated for each protein and the 1.25-fold cutoff was applied to determine what proteins 
were up- and down-regulated. Results were loaded into IPA for protein function analysis. 
2.10. Western blot 
Equal amounts of cell lysate (40 µg) were separated by sodium dodecyl sulfate 
polyacrylamide gel electrophoresis (SDS-PAGE) with an 8% v/v polyacrilamide gel. Proteins 
were transferred to a polyvinylidene difluoride (PVDF) membrane (0.2 µm pore size) by 
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elecroblotting for 90 minutes at 100 V using Mini Trans-Blot Electrophoretic Transfer Cell 
(Bio-Rad). Transfer buffer was 25 mM Tris, 192 mM glycine, 20% v/v ethanol. Membrane 
was blocked with 3% w/v BSA in Tris-buffered saline, 0.1% v/v Tween 20 (TBST) buffer for 
1 hour at room temperature. Primary antibodies were rabbit anti-MYBBP1A and mouse anti-
β-actin diluted at 1:1,000 in 1% w/v BSA in TBST. MYBBP1A (148 kDa) was the target 
protein and β-actin (42 kDa) was used as a loading control. Membrane was cut in half 
between the 50-75 kDa molecular weight marker bands; the top part was incubated with anti-
MYBBP1A primary antibody overnight at 4 ºC, while the bottom part was incubated with 
anti-β-actin primary antibody. Secondary antibodies were alkaline phosphatase conjugated 
anti-rabbit/anti-mouse IgG diluted at 1:3,000 in 1% w/v BSA in TBST buffer. Membranes 
were washed 3 times for 5 minutes with TBST buffer, incubated with corresponding 
secondary antibody for 1 hour at room temperature and washed again 3 times for 5 minutes 
with TBST buffer. Alkaline phosphatase conjugate substrate kit (Bio-Rad) was used to 
measure alkaline phosphatase activity. Membranes were conjugated with substrate for 20 
minutes, washed for 10 minutes in deionized water, dried for 5 minutes in an incubator at 30 
ºC and scanned. ImajeJ was used to measure band density. The density of the MYBBP1A 
bands was normalized dividing by the density of the β-actin bands for each sample. 
Normalized MYBBP1A densities were used to calculate the treated/control expression ratio. 
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CHAPTER 3. RESULTS 
3. 1. Effect of γ-oryzanols on cell viability of A549 cells 
Cytotoxicity of the major components in γ-oryzanol (24-mCAF, CAF, CMF and β-SF) on 
A549 NSCLC cells was tested using an MTT assay. Figure 1 shows the results, where cell 
viability is represented as a percentage of the control. 24-mCAF, CAF and CMF showed 
significant inhibition of cell viability, whereas β-SF did not seem to affect it. Among the four 
γ-oryzanols, 24-mCAF showed the strongest inhibition, which was significant from a 
concentration of 10 µM. Given these results, 24- mCAF was selected for further study. A 
concentration of 50 µM was chosen to ensure an inhibition of more than 40%. 
 
 
Figure 7. Effect of γ-oryzanols on cell viability of A549 cells. Cell viability is represented as a percentage of the 
control. Error bars represent the standard deviation of the mean (SEM). Sample size (n) = 3 
 
3. 1. Quantitative analysis of the changes in protein expression in response to 24-mCAF 
In order to analyze the effect of 24-mCAF in protein expression, an iTRAQ-based 
quantitative proteomic analysis was carried out. A total of 484 proteins were identified. 
However, only 432 were considered to be consistently expressed in the control samples and 
were accepted for analysis (see Section 2.9). A 1.25-fold cutoff was used to determine which 
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proteins were differentially expressed. Distribution of the ratios can be observed in Figure 8, 
where the logarithm of the median is represented against the Mascot score for each protein. A 
total of 58 differentially expressed proteins were identified, 29 of which were up-regulated 
and 29 down-regulated (Appendix). 
Differentially expressed proteins were subjected to IPA and the results revealed that 32 of 
them were cytoplasmic proteins, 18 nuclear, 6 from the plasma membrane and 2 extracellular. 
Twenty of these proteins were enzymes, 9 were transcription factors and 5 were transporters 
(Figure 9). Cellular functions analysis indicated that cell death, apoptosis and cell 
proliferation were the most affected cellular processes by 24-mCAF (Table 3). Cell death and 
apoptosis where activated, whereas cell proliferation was inactivated. Eighteen of the 
differentially expressed proteins contributed to the activation of cell death, 14 to the 
activation of apoptosis and 11 to the inactivation of cell proliferation.  
 
 
Figure 8. Plot of the logarithm of the median of all possible treated/control ratios against Mascot score. Dashed 
red lines indicate the ±1.25-fold cutoff. Dots outside this range represent proteins that are considered to be up- 
or down-regulated by 24-mCAF 
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Figure 9. Differentially expressed proteins after treatment with 24-mCAF. Y-axis represents the median of all 
possible treated/control ratios. X-axis shows the protein ID. Color code indicates in which cell compartment 
proteins are present. Grey labels at the bottom classify proteins by their function.  
 
Table 3. Most affected cellular functions by 24-mCAF. 
Cellular 
functions 
Activation 
State 
P-value 
overlap 
z-score Contributing proteins 
Cell death Activated 1.67E-07  1.477  18  ↑SMARCC1, ↓TPD52, ↓TOP2B, ↓TGM2, 
↓UBQLN1, ↑MYBBP1A, ↓GLS, 
↓SNRPB, ↓NAA15, ↓PSMC6, ↓ATP1A2, 
↓ITGA3, ↓SF3B1, ↓SLC25A10, ↓VAPB, 
↓EIF3E, ↓RPL11, ↑FH 
Apoptosis Activated 9.32E-05 2.062  14  ↑SMARCC1, ↓TPD52, ↓TOP2B, 
↓UBQLN1, ↓SLC25A10, ↓ITGA3, 
↑MYBBP1A, ↓GLS, ↓SF3B1, ↓ATP1A2, 
↑FH, ↓NAA15, ↑TMEM109, ↑HEXB  
Cell 
proliferation 
Inactivated 1.27E02  -0.908  11  ↑WARS, ↓TPD52, ↓TGM2, ↓SF3B1, 
↑SEC23A, ↓PTGES, ↓ITGA3, ↑GPI, 
↓GLS, ↓EIF3E, ↓CA12  
 
Myb binding protein 1A (MYBBP1A) is a transcriptional regulator that acts as tumor 
suppressor by binding to several proteins involved in cancer progression. These proteins 
include P53, NFкB and sirtuin 6 (SIRT6). In this study, MYBBP1A was found to be up-
regulated by 24-mCAF. P53 is a transcription factor well known for its role in cell cycle 
control; its interaction with MYBBP1A allows its activation and induces cell cycle arrest and 
apoptosis. NFкB controls inflammatory processes and cell survival; MYBBP1A inhibits 
transcription of NFкB, leading to inhibition of these processes. SIRT6 is a deacylase known 
18 
 
to act as a metastasis-inducing protein in NSCLC. It inactivates a series of transcription 
factors that control the expression of a large amount of proteins, including the tumor protein 
D52 (TPD52), NADH dehydrogenase ubiquinone 1 beta subcomplex subunit 9 (NDUFB9), 
enoyl-CoA delta isomerase 1 (ECI1), fumarate hydratase (FH), malate dehydrogenase 
(MDH1), vesicle-trafficking protein SEC22B, SEC23A and UPD-glucose glycoprotein 
glucosyltransferase 1 (UGGT1). These 8 proteins were found to be differentially expressed 
after treatment with 24-mCAF and their up- or down-regulation is consistent with 
inactivation of SIRT6. TPD52 and SEC22B are typically over-expressed in NSCLC; they act 
inducing cell migration and invasion and they were down-regulated by 24-mCAF. NDUFB9, 
FH and SEC23A are tumor suppressive proteins involved in the control of cell invasion 
which down-regulation is associated with metastasis. These proteins were up-regulated by 
24-mCAF. The results suggest that the up-regulation of MYBBP1A contributes to stop 
cancer progression via its interaction with proteins directly involved in cancer related 
processes, such as P53 and NFкB, and through the inactivation of SIRT6, which leads to the 
up- or down- regulation of TPD52, NDUFB9, ECI1, FH, MDH1, SEC22B, SEC23A and 
UGGT1 (Figure 10).  
 
Figure 10. Proposed mechanism of action of 24-mCAF in A549 cells 
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3. 3. Western Blot 
Although 24-mCAF is likely to stop cancer progression through different mechanisms, the 
one proposed above connects the higher number of differentially expressed proteins detected 
in this study. Therefore, up-regulation of MYBBP1A was verified by western blot. Band 
density for MYBBP1A was normalized with band density for β- actin. Results are shown in 
Figure 11. MYBBP1A was significantly over-expressed in the sample treated with 24-mCAF 
compared to the control sample. These results confirm the ones obtained with iTRAQ.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Protein  iTRAQ ratio  Western blot ratio 
MYBBP1A  1.42 1.50 
Figure 11. Western blot analysis of the differential expression of 
MYBBP1A in A549 cells treated and non-treated with 24-mCAF.  
(A) 
(B) 
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CHAPTER 4. DISCUSSION 
NSCLC is the most common type of cancer. Its increasing prevalence and the lack of 
effective treatments make the need to find new alternatives to prevent or treat this disease a 
matter of great importance. γ-Oryzanol is a mixture of steryl ferulates found in rice and other 
cereal grains that has shown to have numerous health benefits, including anti-cancer activity 
in prostate cancer cell lines.  The goal of this study was to determine whether the most 
abundant components in the γ-oryzanol mixture (24-mCAF, CAF, CMF and β-SF) have 
cytotoxic activity against A549 NSCLC cells and what are the molecular changes that lead to 
this effect. 
First, the effect of 24-mCAF, CAF, CMF and β-SF on cell viability of A549 cells was tested. 
Results showed that 24-mCAF, CAF and CMF significantly inhibited cell proliferation, 
whereas β-SF did not seem to affect it (Figure 6). From all compounds, 24-mCAF was the 
one that showed the highest inhibitory effect, which was significant from a concentration of 
10 µM after 72 hours of treatment. This concentration is around 100 times lower than the 
concentrations reported for prostate cancer cell lines by Klongpityapoing et al. (2013). This 
might be due to the fact that in previous studies the cytotoxicity of γ-oryzanol on cancer cells 
was tested applying γ-oryzanol as a mixture. Here, the most abundant components of γ-
oryzanol were individually tested and not all of them showed cytotoxicity. This would 
explain that the whole mixture has a weaker effect than the pure compounds. Therefore, 24-
mCAF was selected as the treatment for further experiments. 
In order to better understand the effect of γ-oryzanol on NSCLC, the changes that it causes in 
the proteome were analyzed. A quantitative proteomic approach based on iTRAQ was used to 
identify proteins that were differentially expressed after treatment with 50 µM 24-mCAF for 
72 hours. Although the effects on cell viability of this compound were significant from 10 
µM, a higher concentration was chosen to ensure that there were detectable changes in 
protein expression. A total of 58 differentially expressed proteins were identified, 29 of 
which were up-regulated and 29 down-regulated (Figure 9). 
Analysis with IPA revealed that the cellular processes that were most affected by 24-mCAF 
were cell death, apoptosis, and cell proliferation (Table 3). Cell death and apoptosis were 
activated, whereas cell proliferation was inhibited. There were 18 differentially expressed 
proteins contributing to the activation of cell death, 14 to the activation of apoptosis and 11 to 
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the inhibition of cell proliferation. These results are consistent with the cell viability 
experiments and show that γ-oryzanol has cytotoxic activity on A549 cells. These findings 
also correlate with previous studies in prostate cancer cells, where γ-oryzanol showed to 
induce apoptosis and block cell cycle progression (Hirsch et al., 2015). 
MYBBP1A is a transcriptional regulator localized in the nucleolus that plays an important 
role in early embryonic development and the regulation of inflammation and cell cycle 
progression (George et al., 2015). MYBBP1A acts as a tumor suppressor and it is up-
regulated by 24-mCAF. It was first known to be a c-Myb interacting protein, but it was later 
reported to bind a number of different transcription factors, including P53 and NFкB. 
(Perrera et al., 2010). When nucleolar disruption occurs, MYBBP1A is translocated to the 
nucleoplasm, where it binds P53 and facilitates its tetramerization and activation, inducing 
cell cycle arrest and apoptosis (Ono et al., 2014). MYBBP1A is also a repressor of NFкB, 
which leads to inhibition of inflammatory processes (Owen et al., 2007). Inhibition of NFкB 
by γ-oryzanol was previously reported by Sakai et al. (2012). 
MYBBP1A is also known to bind SRIT6, a member of the mammalian sirtuin family 
(Polyakova et al., 2012). Sirtuins are a conserved group of NAD
+
 dependent proteins with 
deacylase and/ or ADP ribosyltransferase activitiy. SIRT6 possess both activities and acts as 
a regulator of several processes, such as DNA repair, gene expression, telomere maintenance, 
metabolism and aging. This protein plays multiple complex roles in cancer; depending on the 
type of cancer, it can act as a tumor suppressor or as a cancer-inducing protein. In NSCLC, 
SIRT6 is up-regulated. Knockdown of SIRT6 in A459 cells reduces cell migration and 
invasion, whereas its over-expression induces metastasis (Bai et al. 2016). SIRT6 promotes 
the expression of COX-2, a tumor-inducing protein that is involved in cell proliferation and 
survival (Ming et al., 2014). Up-regulation of MYBBP1A produces inactivation of SIRT6, 
which leads to down-regulation of COX-2 and consequently to the inhibition of cell 
proliferation. Reduction of the expression of COX-2 by γ-oryzanol was previously reported 
by Szcześniak et al. (2015). 
SIRT6 is known to indirectly regulate the expression of numerous proteins, including TPD52, 
NDUFB9, ECI1, FH, MDH1, SEC22B, SEC23A and UGGT1. These 8 proteins were found 
to be differentially expressed in this study, and their expression direction indicates that SITR6 
is inactivated. TPD52, SEC22B and UGGT1 were down-regulated by 24-mCAF, whereas 
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NDUFB9, ECI1, FH, MDH1 and SEC23A were up-regulated. The differential expression of 
most of these proteins is consistent with cancer inhibition. 
TPD52 is over-expressed in lung adenocarcioma; its gene is located in chromosome 8q21.13, 
which is one of the most amplified genomic regions in this type of cancer. Its over-expression 
enhances cancer cell aggressiveness and contributes to several oncogenic pathways. 
Knockdown of TPD52 significantly suppresses cancer cell migration and invasion 
(Kumamoto et al., 2016).   
SEC22B is a vesicle-trafficking protein that is involved in lipid metabolism at contact sites 
between the endoplasmic reticulum (ER) and the plasma membrane. Lipid production and 
transfer at these membrane contact sites are essential for membrane expansion, which is 
important in cell migration (Petkovic et al., 2014). Okayama et al. (2014) carried out a 
proteomic study to identify proteins related to prognosis in lung adenocarcinoma and found 
that SEC22B was over-expressed in patients with poor prognosis. 
NDUFB9 is an accessory subunit of the mitochondrial membrane respiratory chain NADH 
dehydrogenase (Complex I) and it is down-regulated in highly metastatic cancer cells. Down-
regulation of NDUFB9 produces complex I deficiency, which disturbs electron transfer and 
leads to a disruption of the NAD
+
/NADH balance. Together with other processes, this 
unbalance induces cell migration and invasion (Li et al. 2015). 
FH converts fumarate to malate in the tricarboxylic acid cycle. Its down-regulation increases 
the amount of intracellular fumaric acid, which inhibits the hydroxylation of the hypoxia-
inducible factor (HIF). If HIF cannot be hydroxylated, it cannot be degraded by the 
proteosome. HIF regulates the expression of several genes like vascular endothelial growth 
factor (VEGF), erythropoietin (EPO), platelet derived growth factor (PDGF), EGFR, glucose 
transporter protein 1 (GLUT-1), and transforming growth factor-alpha (TGF-α). These genes 
are involved in maintaining the energy metabolism of tumor cells, promoting tumor 
angiogenesis, invasion, and metastasis. In A549 cells, FH is significantly under-expressed at 
both mRNA and protein levels compared with non-cancer cells (Ming et al., 2014). 
MDH1 catalyzes the conversion of malate to oxaloacetate in the cytoplasm and it has also 
been reported to be a transcriptional co-activator of P53. It stabilizes and activates it by 
translocating to the nucleus and binding to p53-responsive elements in the promoter of 
downstream genes. When MDH1 is down-regulated, binding of acetylated P53 is 
23 
 
significantly reduced, which results in loss of p53-mediated cell cycle arrest and apoptosis 
(Lee et al., 2009). 
SEC23A is an indispensable component of coat protein Complex II (COPII)-coated vesicles 
that is involved in transporting secretory proteins from the ER to the Golgi apparatus. 
SEC23A is essential for the secretion of components of the extracellular membrane, such as 
collagen and cartilage oligomeric matrix protein, and it is also important in the secretion of 
metastasis suppressive proteins, like Igfbp4 and Tinagl1 (Boyadjiev et al., 2006). Korpal et 
al. (2012) reported that knockdown of SEC23A enhanced metastatic colonization; however, 
overexpression of SEC23A alone was not sufficient to significantly suppress metastasis. 
Given the results obtained, 24-mCAF seems to inhibit cancer progression by causing 
MYBBP1A up-regulation, which contributes to stop cancer progression through different 
mechanisms (Figure 12). Up-regulation of MYBBP1A by 24-mCAF was verified with 
western blot and the results were consistent with those obtained with iTRAQ (Figure 11). 
Nevertheless, this proposed mechanism does not explain all the expression changes detected 
in this study, indicating that 24-mCAF is likely to stop cancer progression via different 
mechanisms. 
 
Figure 12. Cellular diagram of the proposed mechanism of action of 24-mCAF in A549 cells 
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CHAPTER 5. SUMMARY 
The results obtained in this study show that 24-mCAF inhibits cell proliferation of A549 
cells. Anti-cancer effects of γ-oryzanol as a mixture have previously been reported for other 
types of cancer, but not for NSCLC. Here, the 4 most abundant components of γ-oryzanol 
(24-mCAF, CAF, CMF and β-SF) were individually tested. 24-mCAF, CAF and CMF 
inhibited cell proliferation, while β-SF did not. 24-mCAF showed the strongest inhibitory 
effect. 
A quantitative proteomic study using iTRAQ confirmed the cytotoxic effect of 24-mCAF on 
A549 cells. The most affected molecular functions by the changes caused in the proteome 
were cell death and apoptosis, which were activated, and cell proliferation, which was 
inactivated. The results obtained suggest that 24-mCAF produces MYBBP1A up-regulation, 
which leads to cancer inhibition through different mechanisms. These mechanisms include its 
interaction with P53, which induces apoptosis and cell cycle arrest; its interaction with NFкB, 
which inhibits inflammatory processes; and its interaction with SIRT6, which leads to the 
down-regulation of TPD52, SEC22B and UGGT1 and to the up-regulation of NDUFB9, 
ECI1, FH, MDH1 and SEC23A. However, this proposed mechanism does not explain the up- 
or down-regulation of all differentially expressed proteins detected, which suggests that 24-
mCAF probably affects the cell in different ways and inhibits cancer through different 
mechanisms. 
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CHAPTER 6. APPENDIX 
Accession1 Protein 
MW2 
[kDa] 
Scores3 #Peptides4 
SC5 
[%] 
iTRAQ6 
ratio 
CD59_HUMAN 
CD59 glycoprotein OS=Homo sapiens 
GN=CD59 PE=1 SV=1 14.2 25.9 1 9.4 1.77 
NH2L1_HUMAN 
NHP2-like protein 1 OS=Homo sapiens 
GN=SNU13 PE=1 SV=3 14.2 34.3 1 9.4 1.75 
FSCN1_HUMAN 
Fascin OS=Homo sapiens GN=FSCN1 
PE=1 SV=3 54.5 55.6 2 7.5 1.63 
RL28_HUMAN 
60S ribosomal protein L28 OS=Homo 
sapiens GN=RPL28 PE=1 SV=3 15.7 22.8 1 5.1 1.63 
NENF_HUMAN 
Neudesin OS=Homo sapiens GN=NENF 
PE=1 SV=1 18.8 39.9 1 5.2 1.55 
SFXN1_HUMAN 
Sideroflexin-1 OS=Homo sapiens 
GN=SFXN1 PE=1 SV=4 35.6 128.1 3 9.9 1.53 
SYWC_HUMAN 
Tryptophan--tRNA ligase, cytoplasmic 
OS=Homo sapiens GN=WARS PE=1 
SV=2 53.1 48.5 1 3.4 1.52 
FUMH_HUMAN 
Fumarate hydratase, mitochondrial 
OS=Homo sapiens GN=FH PE=1 SV=3 54.6 43.2 1 3.5 1.51 
SMAD9_HUMAN 
Mothers against decapentaplegic homolog 
9 OS=Homo sapiens GN=SMAD9 PE=1 
SV=1 52.5 53.8 1 2.8 1.48 
ECI1_HUMAN 
Enoyl-CoA delta isomerase 1, 
mitochondrial OS=Homo sapiens 
GN=ECI1 PE=1 SV=1 32.8 36 1 4.3 1.48 
PABP1_HUMAN 
Polyadenylate-binding protein 1 OS=Homo 
sapiens GN=PABPC1 PE=1 SV=2 70.6 93.2 3 5.7 1.45 
LAT1_HUMAN 
Large neutral amino acids transporter small 
subunit 1 OS=Homo sapiens GN=SLC7A5 
PE=1 SV=2 55 110.7 3 5.3 1.43 
SMRC1_HUMAN 
SWI/SNF complex subunit SMARCC1 
OS=Homo sapiens GN=SMARCC1 PE=1 
SV=3 122.8 41.5 1 1 1.42 
MBB1A_HUMAN 
Myb-binding protein 1A OS=Homo 
sapiens GN=MYBBP1A PE=1 SV=2 148.8 113 3 2.8 1.42 
NOLC1_HUMAN 
Nucleolar and coiled-body phosphoprotein 
1 OS=Homo sapiens GN=NOLC1 PE=1 
SV=2 73.6 36.1 1 2.1 1.38 
ATP5L_HUMAN 
ATP synthase subunit g, mitochondrial 
OS=Homo sapiens GN=ATP5L PE=1 
SV=3 11.4 74.7 2 27.2 1.34 
RAN_HUMAN 
GTP-binding nuclear protein Ran 
OS=Homo sapiens GN=RAN PE=1 SV=3 24.4 74.4 2 11.1 1.33 
NDUB9_HUMAN 
NADH dehydrogenase [ubiquinone] 1 beta 
subcomplex subunit 9 OS=Homo sapiens 
GN=NDUFB9 PE=1 SV=3 21.8 55.3 2 20.1 1.33 
ZN207_HUMAN 
BUB3-interacting and GLEBS motif-
containing protein ZNF207 OS=Homo 
sapiens GN=ZNF207 PE=1 SV=1 50.7 66.6 1 2.7 1.32 
SNRPA_HUMAN 
U1 small nuclear ribonucleoprotein A 
OS=Homo sapiens GN=SNRPA PE=1 
SV=3 31.3 44.6 1 6.4 1.31 
TM109_HUMAN 
Transmembrane protein 109 OS=Homo 
sapiens GN=TMEM109 PE=1 SV=1 26.2 40.1 1 5.3 1.29 
SC23A_HUMAN 
Protein transport protein Sec23A 
OS=Homo sapiens GN=SEC23A PE=1 
SV=2 86.1 88 2 4.1 1.29 
CX6B1_HUMAN 
Cytochrome c oxidase subunit 6B1 
OS=Homo sapiens GN=COX6B1 PE=1 
SV=2 10.2 68.4 2 20.9 1.29 
HEXB_HUMAN Beta-hexosaminidase subunit beta 63.1 76.9 3 6.1 1.27 
26 
 
OS=Homo sapiens GN=HEXB PE=1 
SV=3 
RS12_HUMAN 
40S ribosomal protein S12 OS=Homo 
sapiens GN=RPS12 PE=1 SV=3 14.5 148.2 4 31.8 1.26 
FUBP1_HUMAN 
Far upstream element-binding protein 1 
OS=Homo sapiens GN=FUBP1 PE=1 
SV=3 67.5 117.9 5 7.9 1.26 
MDHC_HUMAN 
Malate dehydrogenase, cytoplasmic 
OS=Homo sapiens GN=MDH1 PE=1 
SV=4 36.4 103.1 3 11.4 1.26 
G6PI_HUMAN 
Glucose-6-phosphate isomerase OS=Homo 
sapiens GN=GPI PE=1 SV=4 63.1 350.7 12 20.6 1.25 
1433T_HUMAN 
14-3-3 protein theta OS=Homo sapiens 
GN=YWHAQ PE=1 SV=1 27.7 238.2 6 30.2 1.25 
TOM6_HUMAN 
Mitochondrial import receptor subunit 
TOM6 homolog OS=Homo sapiens 
GN=TOMM6 PE=1 SV=1 8 90 3 41.9 1.24 
TMED4_HUMAN 
Transmembrane emp24 domain-containing 
protein 4 OS=Homo sapiens GN=TMED4 
PE=1 SV=1 25.9 59 2 7.5 1.24 
HYOU1_HUMAN 
Hypoxia up-regulated protein 1 OS=Homo 
sapiens GN=HYOU1 PE=1 SV=1 111.3 128.6 5 8.5 1.23 
PARP1_HUMAN 
Poly [ADP-ribose] polymerase 1 
OS=Homo sapiens GN=PARP1 PE=1 
SV=4 113 124.1 4 5.4 1.23 
RL9_HUMAN 
60S ribosomal protein L9 OS=Homo 
sapiens GN=RPL9 PE=1 SV=1 21.8 70.2 2 19.3 1.22 
KAD2_HUMAN 
Adenylate kinase 2, mitochondrial 
OS=Homo sapiens GN=AK2 PE=1 SV=2 26.5 100.5 3 16.7 1.21 
AHSA1_HUMAN 
Activator of 90 kDa heat shock protein 
ATPase homolog 1 OS=Homo sapiens 
GN=AHSA1 PE=1 SV=1 38.3 41.1 1 6.5 1.21 
NP1L1_HUMAN 
Nucleosome assembly protein 1-like 1 
OS=Homo sapiens GN=NAP1L1 PE=1 
SV=1 45.3 91.7 3 12 1.21 
CPNE3_HUMAN 
Copine-3 OS=Homo sapiens GN=CPNE3 
PE=1 SV=1 60.1 32.4 1 1.7 1.21 
ACOT1_HUMAN 
Acyl-coenzyme A thioesterase 1 
OS=Homo sapiens GN=ACOT1 PE=1 
SV=1 46.2 58.7 2 6.4 1.20 
AN32B_HUMAN 
Acidic leucine-rich nuclear phosphoprotein 
32 family member B OS=Homo sapiens 
GN=ANP32B PE=1 SV=1 28.8 53.1 2 10.8 1.19 
RT21_HUMAN 
28S ribosomal protein S21, mitochondrial 
OS=Homo sapiens GN=MRPS21 PE=1 
SV=2 10.7 41.2 1 13.8 1.19 
NDUA5_HUMAN 
NADH dehydrogenase [ubiquinone] 1 
alpha subcomplex subunit 5 OS=Homo 
sapiens GN=NDUFA5 PE=1 SV=3 13.5 69.4 2 30.2 1.19 
PRS6B_HUMAN 
26S protease regulatory subunit 6B 
OS=Homo sapiens GN=PSMC4 PE=1 
SV=2 47.3 99.7 3 10.5 1.18 
RS21_HUMAN 
40S ribosomal protein S21 OS=Homo 
sapiens GN=RPS21 PE=1 SV=1 9.1 57.3 2 22.9 1.18 
AT2A2_HUMAN 
Sarcoplasmic/endoplasmic reticulum 
calcium ATPase 2 OS=Homo sapiens 
GN=ATP2A2 PE=1 SV=1 114.7 269.8 9 13.7 1.17 
VINC_HUMAN 
Vinculin OS=Homo sapiens GN=VCL 
PE=1 SV=4 123.7 76.3 2 2.8 1.16 
BASP1_HUMAN 
Brain acid soluble protein 1 OS=Homo 
sapiens GN=BASP1 PE=1 SV=2 22.7 107.8 3 18.1 1.16 
MGST1_HUMAN 
Microsomal glutathione S-transferase 1 
OS=Homo sapiens GN=MGST1 PE=1 
SV=1 17.6 94.8 2 16.1 1.15 
SET_HUMAN 
Protein SET OS=Homo sapiens GN=SET 
PE=1 SV=3 33.5 57.5 2 8.3 1.15 
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LASP1_HUMAN 
LIM and SH3 domain protein 1 OS=Homo 
sapiens GN=LASP1 PE=1 SV=2 29.7 128.3 5 16.1 1.15 
HMOX1_HUMAN 
Heme oxygenase 1 OS=Homo sapiens 
GN=HMOX1 PE=1 SV=1 32.8 95.2 3 18.4 1.15 
DLDH_HUMAN 
Dihydrolipoyl dehydrogenase, 
mitochondrial OS=Homo sapiens 
GN=DLD PE=1 SV=2 54.1 102.9 3 11.4 1.15 
KLK10_HUMAN 
Kallikrein-10 OS=Homo sapiens 
GN=KLK10 PE=1 SV=3 30.2 15.6 1 2.5 1.15 
TCPD_HUMAN 
T-complex protein 1 subunit delta 
OS=Homo sapiens GN=CCT4 PE=1 SV=4 57.9 175 7 21.5 1.15 
RS13_HUMAN 
40S ribosomal protein S13 OS=Homo 
sapiens GN=RPS13 PE=1 SV=2 17.2 203.8 6 37.1 1.15 
SF3B3_HUMAN 
Splicing factor 3B subunit 3 OS=Homo 
sapiens GN=SF3B3 PE=1 SV=4 135.5 66.9 2 2.7 1.15 
IF2B1_HUMAN 
Insulin-like growth factor 2 mRNA-
binding protein 1 OS=Homo sapiens 
GN=IGF2BP1 PE=1 SV=2 63.4 82.1 2 5.4 1.14 
SODC_HUMAN 
Superoxide dismutase [Cu-Zn] OS=Homo 
sapiens GN=SOD1 PE=1 SV=2 15.9 71.7 2 15.6 1.14 
SYRC_HUMAN 
Arginine--tRNA ligase, cytoplasmic 
OS=Homo sapiens GN=RARS PE=1 SV=2 75.3 106.4 4 7.7 1.13 
PSB7_HUMAN 
Proteasome subunit beta type-7 OS=Homo 
sapiens GN=PSMB7 PE=1 SV=1 29.9 63 2 6.9 1.13 
HNRPM_HUMAN 
Heterogeneous nuclear ribonucleoprotein 
M OS=Homo sapiens GN=HNRNPM 
PE=1 SV=3 77.5 538.1 18 22.6 1.13 
TEBP_HUMAN 
Prostaglandin E synthase 3 OS=Homo 
sapiens GN=PTGES3 PE=1 SV=1 18.7 122.8 4 30.6 1.13 
EF1B_HUMAN 
Elongation factor 1-beta OS=Homo sapiens 
GN=EEF1B2 PE=1 SV=3 24.7 107 3 26.7 1.12 
EMC7_HUMAN 
ER membrane protein complex subunit 7 
OS=Homo sapiens GN=EMC7 PE=1 
SV=1 26.5 43 1 5.4 1.12 
PRDX5_HUMAN 
Peroxiredoxin-5, mitochondrial OS=Homo 
sapiens GN=PRDX5 PE=1 SV=4 22.1 204 6 39.3 1.12 
TM9S2_HUMAN 
Transmembrane 9 superfamily member 2 
OS=Homo sapiens GN=TM9SF2 PE=1 
SV=1 75.7 37.7 1 2.1 1.12 
EF2_HUMAN 
Elongation factor 2 OS=Homo sapiens 
GN=EEF2 PE=1 SV=4 95.3 394.7 10 15.4 1.11 
PSME3_HUMAN 
Proteasome activator complex subunit 3 
OS=Homo sapiens GN=PSME3 PE=1 
SV=1 29.5 69.6 2 8.7 1.11 
AL3A2_HUMAN 
Fatty aldehyde dehydrogenase OS=Homo 
sapiens GN=ALDH3A2 PE=1 SV=1 54.8 53.3 2 6 1.11 
PDIA4_HUMAN 
Protein disulfide-isomerase A4 OS=Homo 
sapiens GN=PDIA4 PE=1 SV=2 72.9 345 10 18 1.11 
NDKB_HUMAN 
Nucleoside diphosphate kinase B 
OS=Homo sapiens GN=NME2 PE=1 
SV=1 17.3 233.7 7 43.4 1.11 
H2AY_HUMAN 
Core histone macro-H2A.1 OS=Homo 
sapiens GN=H2AFY PE=1 SV=4 39.6 208.7 5 18 1.11 
NQO1_HUMAN 
NAD(P)H dehydrogenase [quinone] 1 
OS=Homo sapiens GN=NQO1 PE=1 
SV=1 30.8 217.6 8 20.8 1.11 
HS90A_HUMAN 
Heat shock protein HSP 90-alpha 
OS=Homo sapiens GN=HSP90AA1 PE=1 
SV=5 84.6 816.5 21 36.1 1.11 
ENPL_HUMAN 
Endoplasmin OS=Homo sapiens 
GN=HSP90B1 PE=1 SV=1 92.4 726.9 23 35.7 1.11 
ILF3_HUMAN 
Interleukin enhancer-binding factor 3 
OS=Homo sapiens GN=ILF3 PE=1 SV=3 95.3 275.8 9 12.4 1.11 
THIL_HUMAN 
Acetyl-CoA acetyltransferase, 
mitochondrial OS=Homo sapiens 
GN=ACAT1 PE=1 SV=1 45.2 131.5 6 19.7 1.10 
28 
 
TBB5_HUMAN 
Tubulin beta chain OS=Homo sapiens 
GN=TUBB PE=1 SV=2 49.6 1135.9 29 59 1.10 
PDIA3_HUMAN 
Protein disulfide-isomerase A3 OS=Homo 
sapiens GN=PDIA3 PE=1 SV=4 56.7 473.9 17 34.7 1.10 
PDCD6_HUMAN 
Programmed cell death protein 6 
OS=Homo sapiens GN=PDCD6 PE=1 
SV=1 21.9 50.8 2 19.9 1.10 
RALY_HUMAN 
RNA-binding protein Raly OS=Homo 
sapiens GN=RALY PE=1 SV=1 32.4 29.4 1 2.6 1.10 
TCPQ_HUMAN 
T-complex protein 1 subunit theta 
OS=Homo sapiens GN=CCT8 PE=1 SV=4 59.6 113.4 5 12.2 1.10 
TXND5_HUMAN 
Thioredoxin domain-containing protein 5 
OS=Homo sapiens GN=TXNDC5 PE=1 
SV=2 47.6 110.5 3 10.6 1.10 
CPSM_HUMAN 
Carbamoyl-phosphate synthase [ammonia], 
mitochondrial OS=Homo sapiens 
GN=CPS1 PE=1 SV=2 164.8 98.4 3 2.5 1.10 
2AAA_HUMAN 
Serine/threonine-protein phosphatase 2A 
65 kDa regulatory subunit A alpha isoform 
OS=Homo sapiens GN=PPP2R1A PE=1 
SV=4 65.3 35.7 1 2.2 1.10 
RL24_HUMAN 
60S ribosomal protein L24 OS=Homo 
sapiens GN=RPL24 PE=1 SV=1 17.8 62.2 2 14 1.09 
AK1BF_HUMAN 
Aldo-keto reductase family 1 member B15 
OS=Homo sapiens GN=AKR1B15 PE=1 
SV=2 36.5 228.8 4 12 1.09 
RL12_HUMAN 
60S ribosomal protein L12 OS=Homo 
sapiens GN=RPL12 PE=1 SV=1 17.8 172 4 37.6 1.09 
RL27A_HUMAN 
60S ribosomal protein L27a OS=Homo 
sapiens GN=RPL27A PE=1 SV=2 16.6 165.6 3 20.9 1.09 
RL7_HUMAN 
60S ribosomal protein L7 OS=Homo 
sapiens GN=RPL7 PE=1 SV=1 29.2 101 3 14.1 1.09 
PARK7_HUMAN 
Protein deglycase DJ-1 OS=Homo sapiens 
GN=PARK7 PE=1 SV=2 19.9 159.2 5 25.4 1.09 
TBB4B_HUMAN 
Tubulin beta-4B chain OS=Homo sapiens 
GN=TUBB4B PE=1 SV=1 49.8 1063.7 28 58.9 1.09 
EFTU_HUMAN 
Elongation factor Tu, mitochondrial 
OS=Homo sapiens GN=TUFM PE=1 
SV=2 49.5 407.5 14 34.1 1.09 
S10AD_HUMAN 
Protein S100-A13 OS=Homo sapiens 
GN=S100A13 PE=1 SV=1 11.5 37 1 12.2 1.09 
RL18_HUMAN 
60S ribosomal protein L18 OS=Homo 
sapiens GN=RPL18 PE=1 SV=2 21.6 164.5 5 30.9 1.09 
RS9_HUMAN 
40S ribosomal protein S9 OS=Homo 
sapiens GN=RPS9 PE=1 SV=3 22.6 116 4 16.5 1.09 
HYEP_HUMAN 
Epoxide hydrolase 1 OS=Homo sapiens 
GN=EPHX1 PE=1 SV=1 52.9 237.5 6 16.9 1.09 
ACLY_HUMAN 
ATP-citrate synthase OS=Homo sapiens 
GN=ACLY PE=1 SV=3 120.8 382.6 12 14.6 1.09 
XRCC5_HUMAN 
X-ray repair cross-complementing protein 
5 OS=Homo sapiens GN=XRCC5 PE=1 
SV=3 82.7 195 7 13.3 1.09 
HSP7C_HUMAN 
Heat shock cognate 71 kDa protein 
OS=Homo sapiens GN=HSPA8 PE=1 
SV=1 70.9 916.9 27 49.2 1.08 
EF1A1_HUMAN 
Elongation factor 1-alpha 1 OS=Homo 
sapiens GN=EEF1A1 PE=1 SV=1 50.1 435.3 12 38.7 1.08 
RL14_HUMAN 
60S ribosomal protein L14 OS=Homo 
sapiens GN=RPL14 PE=1 SV=4 23.4 115.1 4 15.3 1.08 
RM12_HUMAN 
39S ribosomal protein L12, mitochondrial 
OS=Homo sapiens GN=MRPL12 PE=1 
SV=2 21.3 121.1 3 29.8 1.08 
MATR3_HUMAN 
Matrin-3 OS=Homo sapiens GN=MATR3 
PE=1 SV=2 94.6 283.2 8 10.7 1.08 
CAZA2_HUMAN 
F-actin-capping protein subunit alpha-2 
OS=Homo sapiens GN=CAPZA2 PE=1 32.9 56.6 2 9.8 1.08 
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SV=3 
AGR2_HUMAN 
Anterior gradient protein 2 homolog 
OS=Homo sapiens GN=AGR2 PE=1 SV=1 20 327.2 8 36 1.08 
RS8_HUMAN 
40S ribosomal protein S8 OS=Homo 
sapiens GN=RPS8 PE=1 SV=2 24.2 93.4 3 13.5 1.07 
AK1C3_HUMAN 
Aldo-keto reductase family 1 member C3 
OS=Homo sapiens GN=AKR1C3 PE=1 
SV=4 36.8 568.1 16 42.4 1.07 
1433Z_HUMAN 
14-3-3 protein zeta/delta OS=Homo 
sapiens GN=YWHAZ PE=1 SV=1 27.7 340.8 10 46.1 1.07 
PROF1_HUMAN 
Profilin-1 OS=Homo sapiens GN=PFN1 
PE=1 SV=2 15 477.6 13 70.7 1.07 
RL4_HUMAN 
60S ribosomal protein L4 OS=Homo 
sapiens GN=RPL4 PE=1 SV=5 47.7 244.5 7 20.8 1.07 
RS10_HUMAN 
40S ribosomal protein S10 OS=Homo 
sapiens GN=RPS10 PE=1 SV=1 18.9 147.2 3 19.4 1.07 
OST48_HUMAN 
Dolichyl-diphosphooligosaccharide--
protein glycosyltransferase 48 kDa subunit 
OS=Homo sapiens GN=DDOST PE=1 
SV=4 50.8 90.6 2 5.3 1.07 
MAP4_HUMAN 
Microtubule-associated protein 4 
OS=Homo sapiens GN=MAP4 PE=1 
SV=3 120.9 71.7 3 4.5 1.07 
RS18_HUMAN 
40S ribosomal protein S18 OS=Homo 
sapiens GN=RPS18 PE=1 SV=3 17.7 207.2 7 32.9 1.07 
SQSTM_HUMAN 
Sequestosome-1 OS=Homo sapiens 
GN=SQSTM1 PE=1 SV=1 47.7 104.7 4 15.5 1.07 
STML2_HUMAN 
Stomatin-like protein 2, mitochondrial 
OS=Homo sapiens GN=STOML2 PE=1 
SV=1 38.5 109.8 4 19.7 1.07 
ERO1A_HUMAN 
ERO1-like protein alpha OS=Homo 
sapiens GN=ERO1A PE=1 SV=2 54.4 58.8 2 4.1 1.07 
RL31_HUMAN 
60S ribosomal protein L31 OS=Homo 
sapiens GN=RPL31 PE=1 SV=1 14.5 118 3 19.2 1.07 
1433B_HUMAN 
14-3-3 protein beta/alpha OS=Homo 
sapiens GN=YWHAB PE=1 SV=3 28.1 220.1 7 27.6 1.07 
ANXA5_HUMAN 
Annexin A5 OS=Homo sapiens 
GN=ANXA5 PE=1 SV=2 35.9 176.5 5 20.9 1.06 
6PGD_HUMAN 
6-phosphogluconate dehydrogenase, 
decarboxylating OS=Homo sapiens 
GN=PGD PE=1 SV=3 53.1 627.9 14 40.8 1.06 
G3P_HUMAN 
Glyceraldehyde-3-phosphate 
dehydrogenase OS=Homo sapiens 
GN=GAPDH PE=1 SV=3 36 1009 25 50.7 1.06 
CISY_HUMAN 
Citrate synthase, mitochondrial OS=Homo 
sapiens GN=CS PE=1 SV=2 51.7 130.4 3 7.7 1.06 
HS90B_HUMAN 
Heat shock protein HSP 90-beta OS=Homo 
sapiens GN=HSP90AB1 PE=1 SV=4 83.2 719 21 39.1 1.06 
AR6P1_HUMAN 
ADP-ribosylation factor-like protein 6-
interacting protein 1 OS=Homo sapiens 
GN=ARL6IP1 PE=1 SV=2 23.3 39.3 1 4.9 1.06 
DSRAD_HUMAN 
Double-stranded RNA-specific adenosine 
deaminase OS=Homo sapiens GN=ADAR 
PE=1 SV=4 136 35.9 1 1 1.06 
RL13_HUMAN 
60S ribosomal protein L13 OS=Homo 
sapiens GN=RPL13 PE=1 SV=4 24.2 176.5 4 14.2 1.06 
GSTP1_HUMAN 
Glutathione S-transferase P OS=Homo 
sapiens GN=GSTP1 PE=1 SV=2 23.3 191.6 5 38.6 1.06 
AATM_HUMAN 
Aspartate aminotransferase, mitochondrial 
OS=Homo sapiens GN=GOT2 PE=1 SV=3 47.5 142.9 5 15.1 1.06 
RS27A_HUMAN 
Ubiquitin-40S ribosomal protein S27a 
OS=Homo sapiens GN=RPS27A PE=1 
SV=2 18 162.9 6 42.3 1.06 
ERP29_HUMAN 
Endoplasmic reticulum resident protein 29 
OS=Homo sapiens GN=ERP29 PE=1 
SV=4 29 177.5 5 27.2 1.06 
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ARF3_HUMAN 
ADP-ribosylation factor 3 OS=Homo 
sapiens GN=ARF3 PE=1 SV=2 20.6 92.5 3 17.7 1.06 
H2A2B_HUMAN 
Histone H2A type 2-B OS=Homo sapiens 
GN=HIST2H2AB PE=1 SV=3 14 289.5 5 57.7 1.06 
CN166_HUMAN 
UPF0568 protein C14orf166 OS=Homo 
sapiens GN=C14orf166 PE=1 SV=1 28.1 145 5 27.9 1.06 
RS16_HUMAN 
40S ribosomal protein S16 OS=Homo 
sapiens GN=RPS16 PE=1 SV=2 16.4 112.2 4 26.7 1.05 
HNRPF_HUMAN 
Heterogeneous nuclear ribonucleoprotein F 
OS=Homo sapiens GN=HNRNPF PE=1 
SV=3 45.6 183.3 5 16.9 1.05 
STIP1_HUMAN 
Stress-induced-phosphoprotein 1 
OS=Homo sapiens GN=STIP1 PE=1 SV=1 62.6 195.6 7 15.5 1.05 
TPIS_HUMAN 
Triosephosphate isomerase OS=Homo 
sapiens GN=TPI1 PE=1 SV=3 30.8 459.3 9 47.6 1.05 
RS25_HUMAN 
40S ribosomal protein S25 OS=Homo 
sapiens GN=RPS25 PE=1 SV=1 13.7 125.4 4 31.2 1.05 
AK1BA_HUMAN 
Aldo-keto reductase family 1 member B10 
OS=Homo sapiens GN=AKR1B10 PE=1 
SV=2 36 610.7 14 38.6 1.05 
CALM_HUMAN 
Calmodulin OS=Homo sapiens 
GN=CALM1 PE=1 SV=2 16.8 233.2 6 47.7 1.05 
PHB_HUMAN 
Prohibitin OS=Homo sapiens GN=PHB 
PE=1 SV=1 29.8 285.5 6 34.6 1.04 
FLNA_HUMAN 
Filamin-A OS=Homo sapiens GN=FLNA 
PE=1 SV=4 280.6 989.4 30 17.3 1.04 
H12_HUMAN 
Histone H1.2 OS=Homo sapiens 
GN=HIST1H1C PE=1 SV=2 21.4 263.4 8 27.2 1.04 
HS71A_HUMAN 
Heat shock 70 kDa protein 1A OS=Homo 
sapiens GN=HSPA1A PE=1 SV=1 70 809.2 19 38.1 1.04 
NONO_HUMAN 
Non-POU domain-containing octamer-
binding protein OS=Homo sapiens 
GN=NONO PE=1 SV=4 54.2 409.9 11 16.8 1.04 
LMNB1_HUMAN 
Lamin-B1 OS=Homo sapiens 
GN=LMNB1 PE=1 SV=2 66.4 200.9 6 14 1.04 
S10A6_HUMAN 
Protein S100-A6 OS=Homo sapiens 
GN=S100A6 PE=1 SV=1 10.2 108.2 3 16.7 1.04 
MDHM_HUMAN 
Malate dehydrogenase, mitochondrial 
OS=Homo sapiens GN=MDH2 PE=1 
SV=3 35.5 567.8 15 56.2 1.04 
PPIB_HUMAN 
Peptidyl-prolyl cis-trans isomerase B 
OS=Homo sapiens GN=PPIB PE=1 SV=2 23.7 258.8 8 26.9 1.04 
CH60_HUMAN 
60 kDa heat shock protein, mitochondrial 
OS=Homo sapiens GN=HSPD1 PE=1 
SV=2 61 1608.9 36 61.1 1.04 
AHNK_HUMAN 
Neuroblast differentiation-associated 
protein AHNAK OS=Homo sapiens 
GN=AHNAK PE=1 SV=2 628.7 330.3 12 2.9 1.04 
H2AV_HUMAN 
Histone H2A.V OS=Homo sapiens 
GN=H2AFV PE=1 SV=3 13.5 161 4 31.2 1.04 
PFKAP_HUMAN 
ATP-dependent 6-phosphofructokinase, 
platelet type OS=Homo sapiens GN=PFKP 
PE=1 SV=2 85.5 76.3 2 5 1.04 
H4_HUMAN 
Histone H4 OS=Homo sapiens 
GN=HIST1H4A PE=1 SV=2 11.4 493.6 12 58.3 1.04 
PPIA_HUMAN 
Peptidyl-prolyl cis-trans isomerase A 
OS=Homo sapiens GN=PPIA PE=1 SV=2 18 520.8 11 47.3 1.04 
RPN1_HUMAN 
Dolichyl-diphosphooligosaccharide--
protein glycosyltransferase subunit 1 
OS=Homo sapiens GN=RPN1 PE=1 SV=1 68.5 157.2 5 10 1.04 
ASPH_HUMAN 
Aspartyl/asparaginyl beta-hydroxylase 
OS=Homo sapiens GN=ASPH PE=1 SV=3 85.8 80.1 3 5.3 1.04 
ITB1_HUMAN 
Integrin beta-1 OS=Homo sapiens 
GN=ITGB1 PE=1 SV=2 88.4 203.1 7 11.4 1.03 
S10AA_HUMAN Protein S100-A10 OS=Homo sapiens 11.2 40.9 1 17.5 1.03 
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GN=S100A10 PE=1 SV=2 
RS2_HUMAN 
40S ribosomal protein S2 OS=Homo 
sapiens GN=RPS2 PE=1 SV=2 31.3 181.8 5 20.1 1.03 
PDXK_HUMAN 
Pyridoxal kinase OS=Homo sapiens 
GN=PDXK PE=1 SV=1 35.1 67.2 2 11.5 1.03 
RAB7A_HUMAN 
Ras-related protein Rab-7a OS=Homo 
sapiens GN=RAB7A PE=1 SV=1 23.5 120.3 4 28.5 1.03 
VDAC1_HUMAN 
Voltage-dependent anion-selective channel 
protein 1 OS=Homo sapiens GN=VDAC1 
PE=1 SV=2 30.8 158.3 5 23.7 1.03 
RL17_HUMAN 
60S ribosomal protein L17 OS=Homo 
sapiens GN=RPL17 PE=1 SV=3 21.4 125 3 14.1 1.03 
AK1C2_HUMAN 
Aldo-keto reductase family 1 member C2 
OS=Homo sapiens GN=AKR1C2 PE=1 
SV=3 36.7 516.2 18 51.1 1.03 
RS5_HUMAN 
40S ribosomal protein S5 OS=Homo 
sapiens GN=RPS5 PE=1 SV=4 22.9 198.4 4 18.6 1.03 
THIO_HUMAN 
Thioredoxin OS=Homo sapiens GN=TXN 
PE=1 SV=3 11.7 173.1 4 38.1 1.03 
ML12B_HUMAN 
Myosin regulatory light chain 12B 
OS=Homo sapiens GN=MYL12B PE=1 
SV=2 19.8 82.8 3 26.2 1.03 
ANXA1_HUMAN 
Annexin A1 OS=Homo sapiens 
GN=ANXA1 PE=1 SV=2 38.7 540.9 11 39.6 1.03 
RSSA_HUMAN 
40S ribosomal protein SA OS=Homo 
sapiens GN=RPSA PE=1 SV=4 32.8 166 4 17.6 1.03 
ECHA_HUMAN 
Trifunctional enzyme subunit alpha, 
mitochondrial OS=Homo sapiens 
GN=HADHA PE=1 SV=2 82.9 301.3 10 19.9 1.03 
ALDR_HUMAN 
Aldose reductase OS=Homo sapiens 
GN=AKR1B1 PE=1 SV=3 35.8 166.7 7 18 1.03 
GSHR_HUMAN 
Glutathione reductase, mitochondrial 
OS=Homo sapiens GN=GSR PE=1 SV=2 56.2 65.9 2 5 1.02 
RTN4_HUMAN 
Reticulon-4 OS=Homo sapiens GN=RTN4 
PE=1 SV=2 129.9 173.3 4 6 1.02 
HP1B3_HUMAN 
Heterochromatin protein 1-binding protein 
3 OS=Homo sapiens GN=HP1BP3 PE=1 
SV=1 61.2 112.7 4 9 1.02 
RBP56_HUMAN 
TATA-binding protein-associated factor 
2N OS=Homo sapiens GN=TAF15 PE=1 
SV=1 61.8 93.3 3 5.2 1.02 
GRP78_HUMAN 
78 kDa glucose-regulated protein 
OS=Homo sapiens GN=HSPA5 PE=1 
SV=2 72.3 896 21 33.9 1.02 
GRP75_HUMAN 
Stress-70 protein, mitochondrial OS=Homo 
sapiens GN=HSPA9 PE=1 SV=2 73.6 911.3 21 35.5 1.02 
HINT2_HUMAN 
Histidine triad nucleotide-binding protein 
2, mitochondrial OS=Homo sapiens 
GN=HINT2 PE=1 SV=1 17.2 128.5 4 41.7 1.02 
F136A_HUMAN 
Protein FAM136A OS=Homo sapiens 
GN=FAM136A PE=1 SV=1 15.6 40.6 1 13 1.02 
1433E_HUMAN 
14-3-3 protein epsilon OS=Homo sapiens 
GN=YWHAE PE=1 SV=1 29.2 286.7 8 27.8 1.02 
MIC60_HUMAN 
MICOS complex subunit MIC60 
OS=Homo sapiens GN=IMMT PE=1 
SV=1 83.6 75.2 3 4.6 1.02 
MVP_HUMAN 
Major vault protein OS=Homo sapiens 
GN=MVP PE=1 SV=4 99.3 141.4 5 7.4 1.02 
ANXA2_HUMAN 
Annexin A2 OS=Homo sapiens 
GN=ANXA2 PE=1 SV=2 38.6 1002.2 27 61.9 1.02 
1433G_HUMAN 
14-3-3 protein gamma OS=Homo sapiens 
GN=YWHAG PE=1 SV=2 28.3 208.3 7 24.3 1.02 
CYB5B_HUMAN 
Cytochrome b5 type B OS=Homo sapiens 
GN=CYB5B PE=1 SV=2 16.3 148.7 4 14.4 1.02 
BLVRB_HUMAN Flavin reductase (NADPH) OS=Homo 22.1 121.1 4 23.8 1.02 
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sapiens GN=BLVRB PE=1 SV=3 
HNRPC_HUMAN 
Heterogeneous nuclear ribonucleoproteins 
C1/C2 OS=Homo sapiens GN=HNRNPC 
PE=1 SV=4 33.6 327.5 8 24.5 1.02 
DDX24_HUMAN 
ATP-dependent RNA helicase DDX24 
OS=Homo sapiens GN=DDX24 PE=1 
SV=1 96.3 84.4 2 4.3 1.01 
H2AJ_HUMAN 
Histone H2A.J OS=Homo sapiens 
GN=H2AFJ PE=1 SV=1 14 300.6 6 60.5 1.01 
TLN1_HUMAN 
Talin-1 OS=Homo sapiens GN=TLN1 
PE=1 SV=3 269.6 183.8 6 3.8 1.01 
PCBP1_HUMAN 
Poly(rC)-binding protein 1 OS=Homo 
sapiens GN=PCBP1 PE=1 SV=2 37.5 255.9 8 24.2 1.01 
PRDX1_HUMAN 
Peroxiredoxin-1 OS=Homo sapiens 
GN=PRDX1 PE=1 SV=1 22.1 365.8 10 50.8 1.01 
DDX3X_HUMAN 
ATP-dependent RNA helicase DDX3X 
OS=Homo sapiens GN=DDX3X PE=1 
SV=3 73.2 181.9 7 12.5 1.01 
EF1G_HUMAN 
Elongation factor 1-gamma OS=Homo 
sapiens GN=EEF1G PE=1 SV=3 50.1 127.5 4 12.4 1.01 
ETFB_HUMAN 
Electron transfer flavoprotein subunit beta 
OS=Homo sapiens GN=ETFB PE=1 SV=3 27.8 163.5 7 26.3 1.01 
KPYM_HUMAN 
Pyruvate kinase PKM OS=Homo sapiens 
GN=PKM PE=1 SV=4 57.9 1220.8 31 61.4 1.01 
H2A2C_HUMAN 
Histone H2A type 2-C OS=Homo sapiens 
GN=HIST2H2AC PE=1 SV=4 14 377 7 60.5 1.01 
LYRIC_HUMAN 
Protein LYRIC OS=Homo sapiens 
GN=MTDH PE=1 SV=2 63.8 59.3 2 4 1.01 
RLA2_HUMAN 
60S acidic ribosomal protein P2 OS=Homo 
sapiens GN=RPLP2 PE=1 SV=1 11.7 144.1 4 69.6 1.01 
AL1B1_HUMAN 
Aldehyde dehydrogenase X, mitochondrial 
OS=Homo sapiens GN=ALDH1B1 PE=1 
SV=3 57.2 137.2 5 13.9 1.01 
ADT3_HUMAN 
ADP/ATP translocase 3 OS=Homo sapiens 
GN=SLC25A6 PE=1 SV=4 32.8 405 12 44 1.01 
IQGA1_HUMAN 
Ras GTPase-activating-like protein 
IQGAP1 OS=Homo sapiens GN=IQGAP1 
PE=1 SV=1 189.1 150.9 4 4.5 1.01 
COX5B_HUMAN 
Cytochrome c oxidase subunit 5B, 
mitochondrial OS=Homo sapiens 
GN=COX5B PE=1 SV=2 13.7 81.1 3 24 1.01 
SMD1_HUMAN 
Small nuclear ribonucleoprotein Sm D1 
OS=Homo sapiens GN=SNRPD1 PE=1 
SV=1 13.3 64.9 2 27.7 1.01 
PP1G_HUMAN 
Serine/threonine-protein phosphatase PP1-
gamma catalytic subunit OS=Homo 
sapiens GN=PPP1CC PE=1 SV=1 37 53.6 2 8.7 1.01 
MYH9_HUMAN 
Myosin-9 OS=Homo sapiens GN=MYH9 
PE=1 SV=4 226.4 927.7 28 18.7 1.00 
PGK1_HUMAN 
Phosphoglycerate kinase 1 OS=Homo 
sapiens GN=PGK1 PE=1 SV=3 44.6 347.3 9 28.3 1.00 
RL23_HUMAN 
60S ribosomal protein L23 OS=Homo 
sapiens GN=RPL23 PE=1 SV=1 14.9 132.1 4 31.4 1.00 
RL15_HUMAN 
60S ribosomal protein L15 OS=Homo 
sapiens GN=RPL15 PE=1 SV=2 24.1 56 2 10.3 1.00 
G6PD_HUMAN 
Glucose-6-phosphate 1-dehydrogenase 
OS=Homo sapiens GN=G6PD PE=1 SV=4 59.2 791.7 25 48.9 1.00 
TERA_HUMAN 
Transitional endoplasmic reticulum 
ATPase OS=Homo sapiens GN=VCP 
PE=1 SV=4 89.3 554.8 18 28.7 1.00 
TPM3_HUMAN 
Tropomyosin alpha-3 chain OS=Homo 
sapiens GN=TPM3 PE=1 SV=2 32.9 113.6 3 11.6 1.00 
COX5A_HUMAN 
Cytochrome c oxidase subunit 5A, 
mitochondrial OS=Homo sapiens 
GN=COX5A PE=1 SV=2 16.8 83 3 25.3 1.00 
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TCPA_HUMAN 
T-complex protein 1 subunit alpha 
OS=Homo sapiens GN=TCP1 PE=1 SV=1 60.3 111.5 5 10.4 1.00 
ACTN1_HUMAN 
Alpha-actinin-1 OS=Homo sapiens 
GN=ACTN1 PE=1 SV=2 103 455.8 14 19.7 1.00 
PDIA6_HUMAN 
Protein disulfide-isomerase A6 OS=Homo 
sapiens GN=PDIA6 PE=1 SV=1 48.1 354.2 8 32.3 1.00 
CALR_HUMAN 
Calreticulin OS=Homo sapiens GN=CALR 
PE=1 SV=1 48.1 264 10 33.1 1.00 
CH10_HUMAN 
10 kDa heat shock protein, mitochondrial 
OS=Homo sapiens GN=HSPE1 PE=1 
SV=2 10.9 258.5 7 66.7 1.00 
AL3A1_HUMAN 
Aldehyde dehydrogenase, dimeric NADP-
preferring OS=Homo sapiens 
GN=ALDH3A1 PE=1 SV=3 50.4 360.2 9 25.4 1.00 
RS3A_HUMAN 
40S ribosomal protein S3a OS=Homo 
sapiens GN=RPS3A PE=1 SV=2 29.9 160.5 4 16.7 1.00 
PDIA1_HUMAN 
Protein disulfide-isomerase OS=Homo 
sapiens GN=P4HB PE=1 SV=3 57.1 631.7 18 33.5 0.99 
CALX_HUMAN 
Calnexin OS=Homo sapiens GN=CANX 
PE=1 SV=2 67.5 406.8 10 17.9 0.99 
TPM4_HUMAN 
Tropomyosin alpha-4 chain OS=Homo 
sapiens GN=TPM4 PE=1 SV=3 28.5 100.4 2 8.1 0.99 
HNRPQ_HUMAN 
Heterogeneous nuclear ribonucleoprotein Q 
OS=Homo sapiens GN=SYNCRIP PE=1 
SV=2 69.6 262.9 7 13.6 0.99 
LDHA_HUMAN 
L-lactate dehydrogenase A chain 
OS=Homo sapiens GN=LDHA PE=1 
SV=2 36.7 436.4 12 43.4 0.99 
ACTG_HUMAN 
Actin, cytoplasmic 2 OS=Homo sapiens 
GN=ACTG1 PE=1 SV=1 41.8 1514.5 34 60.8 0.99 
H2B1K_HUMAN 
Histone H2B type 1-K OS=Homo sapiens 
GN=HIST1H2BK PE=1 SV=3 13.9 622 13 53.2 0.99 
ROA1_HUMAN 
Heterogeneous nuclear ribonucleoprotein 
A1 OS=Homo sapiens GN=HNRNPA1 
PE=1 SV=5 38.7 668.1 16 31.2 0.99 
RL36_HUMAN 
60S ribosomal protein L36 OS=Homo 
sapiens GN=RPL36 PE=1 SV=3 12.2 119.2 3 21 0.99 
AIFM1_HUMAN 
Apoptosis-inducing factor 1, mitochondrial 
OS=Homo sapiens GN=AIFM1 PE=1 
SV=1 66.9 91.5 2 5.4 0.99 
RHOA_HUMAN 
Transforming protein RhoA OS=Homo 
sapiens GN=RHOA PE=1 SV=1 21.8 50.9 2 13 0.99 
RBMX_HUMAN 
RNA-binding motif protein, X 
chromosome OS=Homo sapiens 
GN=RBMX PE=1 SV=3 42.3 147.6 5 11 0.99 
MIF_HUMAN 
Macrophage migration inhibitory factor 
OS=Homo sapiens GN=MIF PE=1 SV=4 12.5 57.8 2 17.4 0.99 
CKAP4_HUMAN 
Cytoskeleton-associated protein 4 
OS=Homo sapiens GN=CKAP4 PE=1 
SV=2 66 324.2 9 21.8 0.99 
PA1B3_HUMAN 
Platelet-activating factor acetylhydrolase 
IB subunit gamma OS=Homo sapiens 
GN=PAFAH1B3 PE=1 SV=1 25.7 64.8 2 11.3 0.99 
ANXA4_HUMAN 
Annexin A4 OS=Homo sapiens 
GN=ANXA4 PE=1 SV=4 35.9 236.4 7 29.2 0.99 
ROA2_HUMAN 
Heterogeneous nuclear ribonucleoproteins 
A2/B1 OS=Homo sapiens 
GN=HNRNPA2B1 PE=1 SV=2 37.4 610.9 19 44.8 0.99 
PSMD2_HUMAN 
26S proteasome non-ATPase regulatory 
subunit 2 OS=Homo sapiens GN=PSMD2 
PE=1 SV=3 100.1 111.3 2 4.1 0.98 
PGRC2_HUMAN 
Membrane-associated progesterone 
receptor component 2 OS=Homo sapiens 
GN=PGRMC2 PE=1 SV=1 23.8 124 2 12.6 0.98 
SAP_HUMAN 
Prosaposin OS=Homo sapiens GN=PSAP 
PE=1 SV=2 58.1 146.3 6 12.2 0.98 
34 
 
PRKDC_HUMAN 
DNA-dependent protein kinase catalytic 
subunit OS=Homo sapiens GN=PRKDC 
PE=1 SV=3 468.8 486 20 6.2 0.98 
CALU_HUMAN 
Calumenin OS=Homo sapiens GN=CALU 
PE=1 SV=2 37.1 86.6 3 13.3 0.98 
LONM_HUMAN 
Lon protease homolog, mitochondrial 
OS=Homo sapiens GN=LONP1 PE=1 
SV=2 106.4 96.2 4 7.4 0.98 
PRDX3_HUMAN 
Thioredoxin-dependent peroxide reductase, 
mitochondrial OS=Homo sapiens 
GN=PRDX3 PE=1 SV=3 27.7 103.2 2 10.2 0.98 
ALDH2_HUMAN 
Aldehyde dehydrogenase, mitochondrial 
OS=Homo sapiens GN=ALDH2 PE=1 
SV=2 56.3 181.9 7 16.1 0.98 
SFPQ_HUMAN 
Splicing factor, proline- and glutamine-rich 
OS=Homo sapiens GN=SFPQ PE=1 SV=2 76.1 171.3 6 6.6 0.98 
RCN1_HUMAN 
Reticulocalbin-1 OS=Homo sapiens 
GN=RCN1 PE=1 SV=1 38.9 90.9 3 9.4 0.98 
ACTC_HUMAN 
Actin, alpha cardiac muscle 1 OS=Homo 
sapiens GN=ACTC1 PE=1 SV=1 42 844.3 21 37.4 0.98 
ROA3_HUMAN 
Heterogeneous nuclear ribonucleoprotein 
A3 OS=Homo sapiens GN=HNRNPA3 
PE=1 SV=2 39.6 226.2 6 15.6 0.98 
NPM_HUMAN 
Nucleophosmin OS=Homo sapiens 
GN=NPM1 PE=1 SV=2 32.6 612.8 11 30.6 0.98 
HNRH1_HUMAN 
Heterogeneous nuclear ribonucleoprotein H 
OS=Homo sapiens GN=HNRNPH1 PE=1 
SV=4 49.2 255.4 7 23.2 0.98 
PHS_HUMAN 
Pterin-4-alpha-carbinolamine dehydratase 
OS=Homo sapiens GN=PCBD1 PE=1 
SV=2 12 66 2 15.4 0.98 
UGDH_HUMAN 
UDP-glucose 6-dehydrogenase OS=Homo 
sapiens GN=UGDH PE=1 SV=1 55 469.2 14 40.5 0.98 
H2B1B_HUMAN 
Histone H2B type 1-B OS=Homo sapiens 
GN=HIST1H2BB PE=1 SV=2 13.9 589.1 12 53.2 0.98 
AL1A1_HUMAN 
Retinal dehydrogenase 1 OS=Homo 
sapiens GN=ALDH1A1 PE=1 SV=2 54.8 1157.1 29 52.3 0.98 
BAF_HUMAN 
Barrier-to-autointegration factor OS=Homo 
sapiens GN=BANF1 PE=1 SV=1 10.1 143.1 5 56.2 0.98 
COF1_HUMAN 
Cofilin-1 OS=Homo sapiens GN=CFL1 
PE=1 SV=3 18.5 226.1 6 50.6 0.98 
H33_HUMAN 
Histone H3.3 OS=Homo sapiens 
GN=H3F3A PE=1 SV=2 15.3 89.9 3 16.9 0.98 
HCD2_HUMAN 
3-hydroxyacyl-CoA dehydrogenase type-2 
OS=Homo sapiens GN=HSD17B10 PE=1 
SV=3 26.9 124 5 24.5 0.98 
HNRDL_HUMAN 
Heterogeneous nuclear ribonucleoprotein 
D-like OS=Homo sapiens GN=HNRNPDL 
PE=1 SV=3 46.4 89.8 3 7.1 0.98 
FLNB_HUMAN 
Filamin-B OS=Homo sapiens GN=FLNB 
PE=1 SV=2 278 825.7 25 13.5 0.98 
DHX9_HUMAN 
ATP-dependent RNA helicase A 
OS=Homo sapiens GN=DHX9 PE=1 
SV=4 140.9 407.7 14 13.7 0.97 
ACADV_HUMAN 
Very long-chain specific acyl-CoA 
dehydrogenase, mitochondrial OS=Homo 
sapiens GN=ACADVL PE=1 SV=1 70.3 65.8 2 4 0.97 
RS6_HUMAN 
40S ribosomal protein S6 OS=Homo 
sapiens GN=RPS6 PE=1 SV=1 28.7 124.9 5 19.3 0.97 
MYL6_HUMAN 
Myosin light polypeptide 6 OS=Homo 
sapiens GN=MYL6 PE=1 SV=2 16.9 162.8 6 39.1 0.97 
DDX5_HUMAN 
Probable ATP-dependent RNA helicase 
DDX5 OS=Homo sapiens GN=DDX5 
PE=1 SV=1 69.1 167.6 5 10.3 0.97 
SPTN1_HUMAN 
Spectrin alpha chain, non-erythrocytic 1 
OS=Homo sapiens GN=SPTAN1 PE=1 284.4 425.7 15 7.4 0.97 
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SV=3 
PHB2_HUMAN 
Prohibitin-2 OS=Homo sapiens GN=PHB2 
PE=1 SV=2 33.3 335.3 9 37.1 0.97 
SRSF1_HUMAN 
Serine/arginine-rich splicing factor 1 
OS=Homo sapiens GN=SRSF1 PE=1 
SV=2 27.7 85.4 4 15.7 0.97 
RL3_HUMAN 
60S ribosomal protein L3 OS=Homo 
sapiens GN=RPL3 PE=1 SV=2 46.1 147.5 6 18.4 0.97 
MPRD_HUMAN 
Cation-dependent mannose-6-phosphate 
receptor OS=Homo sapiens GN=M6PR 
PE=1 SV=1 31 36.4 1 7.6 0.97 
HNRPR_HUMAN 
Heterogeneous nuclear ribonucleoprotein R 
OS=Homo sapiens GN=HNRNPR PE=1 
SV=1 70.9 152.1 6 8.1 0.97 
CD44_HUMAN 
CD44 antigen OS=Homo sapiens 
GN=CD44 PE=1 SV=3 81.5 235 5 6.3 0.97 
ATPB_HUMAN 
ATP synthase subunit beta, mitochondrial 
OS=Homo sapiens GN=ATP5B PE=1 
SV=3 56.5 814.7 24 45.9 0.97 
PCBP2_HUMAN 
Poly(rC)-binding protein 2 OS=Homo 
sapiens GN=PCBP2 PE=1 SV=1 38.6 243.4 8 22.5 0.97 
IF5A1_HUMAN 
Eukaryotic translation initiation factor 5A-
1 OS=Homo sapiens GN=EIF5A PE=1 
SV=2 16.8 91.6 2 23.4 0.97 
PTBP1_HUMAN 
Polypyrimidine tract-binding protein 1 
OS=Homo sapiens GN=PTBP1 PE=1 
SV=1 57.2 219.6 4 15.4 0.97 
LEG1_HUMAN 
Galectin-1 OS=Homo sapiens 
GN=LGALS1 PE=1 SV=2 14.7 86.4 3 26.7 0.97 
U520_HUMAN 
U5 small nuclear ribonucleoprotein 200 
kDa helicase OS=Homo sapiens 
GN=SNRNP200 PE=1 SV=2 244.4 113.9 4 2.4 0.97 
RL10_HUMAN 
60S ribosomal protein L10 OS=Homo 
sapiens GN=RPL10 PE=1 SV=4 24.6 134.5 5 27.6 0.97 
SSBP_HUMAN 
Single-stranded DNA-binding protein, 
mitochondrial OS=Homo sapiens 
GN=SSBP1 PE=1 SV=1 17.2 98.4 2 22.3 0.96 
LMNA_HUMAN 
Prelamin-A/C OS=Homo sapiens 
GN=LMNA PE=1 SV=1 74.1 672.8 20 34 0.96 
TKT_HUMAN 
Transketolase OS=Homo sapiens 
GN=TKT PE=1 SV=3 67.8 692.8 17 29.5 0.96 
ATPA_HUMAN 
ATP synthase subunit alpha, mitochondrial 
OS=Homo sapiens GN=ATP5A1 PE=1 
SV=1 59.7 763 19 39.1 0.96 
EF1D_HUMAN 
Elongation factor 1-delta OS=Homo 
sapiens GN=EEF1D PE=1 SV=5 31.1 157.6 4 17.4 0.96 
COX2_HUMAN 
Cytochrome c oxidase subunit 2 OS=Homo 
sapiens GN=MT-CO2 PE=1 SV=1 25.5 35.4 1 4.4 0.96 
SYMC_HUMAN 
Methionine--tRNA ligase, cytoplasmic 
OS=Homo sapiens GN=MARS PE=1 
SV=2 101.1 81.1 3 4.4 0.96 
IF2A_HUMAN 
Eukaryotic translation initiation factor 2 
subunit 1 OS=Homo sapiens GN=EIF2S1 
PE=1 SV=3 36.1 60.1 2 7 0.96 
RS28_HUMAN 
40S ribosomal protein S28 OS=Homo 
sapiens GN=RPS28 PE=1 SV=1 7.8 73.4 2 30.4 0.96 
PSB1_HUMAN 
Proteasome subunit beta type-1 OS=Homo 
sapiens GN=PSMB1 PE=1 SV=2 26.5 82 2 13.3 0.96 
LDHB_HUMAN 
L-lactate dehydrogenase B chain 
OS=Homo sapiens GN=LDHB PE=1 
SV=2 36.6 329.9 9 28.4 0.96 
CLH1_HUMAN 
Clathrin heavy chain 1 OS=Homo sapiens 
GN=CLTC PE=1 SV=5 191.5 883.1 28 21.1 0.96 
NDUS1_HUMAN 
NADH-ubiquinone oxidoreductase 75 kDa 
subunit, mitochondrial OS=Homo sapiens 
GN=NDUFS1 PE=1 SV=3 79.4 37.8 1 2.1 0.96 
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RL6_HUMAN 
60S ribosomal protein L6 OS=Homo 
sapiens GN=RPL6 PE=1 SV=3 32.7 254.4 7 21.5 0.95 
C1QBP_HUMAN 
Complement component 1 Q 
subcomponent-binding protein, 
mitochondrial OS=Homo sapiens 
GN=C1QBP PE=1 SV=1 31.3 381.3 9 40.8 0.95 
KHDR1_HUMAN 
KH domain-containing, RNA-binding, 
signal transduction-associated protein 1 
OS=Homo sapiens GN=KHDRBS1 PE=1 
SV=1 48.2 63.2 2 6.5 0.95 
ILF2_HUMAN 
Interleukin enhancer-binding factor 2 
OS=Homo sapiens GN=ILF2 PE=1 SV=2 43 184 6 22.1 0.95 
TCPB_HUMAN 
T-complex protein 1 subunit beta 
OS=Homo sapiens GN=CCT2 PE=1 SV=4 57.5 340.8 8 21.1 0.95 
CDC42_HUMAN 
Cell division control protein 42 homolog 
OS=Homo sapiens GN=CDC42 PE=1 
SV=2 21.2 115.6 3 20.9 0.95 
HNRPK_HUMAN 
Heterogeneous nuclear ribonucleoprotein K 
OS=Homo sapiens GN=HNRNPK PE=1 
SV=1 50.9 511.9 16 36.7 0.95 
PON2_HUMAN 
Serum paraoxonase/arylesterase 2 
OS=Homo sapiens GN=PON2 PE=1 SV=3 39.4 93.5 3 11.9 0.95 
VIME_HUMAN 
Vimentin OS=Homo sapiens GN=VIM 
PE=1 SV=4 53.6 1394.8 34 56.7 0.95 
RAB1C_HUMAN 
Putative Ras-related protein Rab-1C 
OS=Homo sapiens GN=RAB1C PE=5 
SV=2 22 132.2 4 22.9 0.95 
GDIB_HUMAN 
Rab GDP dissociation inhibitor beta 
OS=Homo sapiens GN=GDI2 PE=1 SV=2 50.6 37.3 1 2.5 0.94 
TBA1B_HUMAN 
Tubulin alpha-1B chain OS=Homo sapiens 
GN=TUBA1B PE=1 SV=1 50.1 803.8 17 45.5 0.94 
SFXN3_HUMAN 
Sideroflexin-3 OS=Homo sapiens 
GN=SFXN3 PE=1 SV=2 36 94 3 10.5 0.94 
PTMS_HUMAN 
Parathymosin OS=Homo sapiens 
GN=PTMS PE=1 SV=2 11.5 52.2 1 10.8 0.94 
TBA1C_HUMAN 
Tubulin alpha-1C chain OS=Homo sapiens 
GN=TUBA1C PE=1 SV=1 49.9 673.8 16 41 0.93 
SRSF2_HUMAN 
Serine/arginine-rich splicing factor 2 
OS=Homo sapiens GN=SRSF2 PE=1 
SV=4 25.5 182.8 5 11.8 0.93 
PLEC_HUMAN 
Plectin OS=Homo sapiens GN=PLEC 
PE=1 SV=3 531.5 1789.8 59 17.3 0.93 
ECH1_HUMAN 
Delta(3,5)-Delta(2,4)-dienoyl-CoA 
isomerase, mitochondrial OS=Homo 
sapiens GN=ECH1 PE=1 SV=2 35.8 273.1 7 23.8 0.93 
LRC59_HUMAN 
Leucine-rich repeat-containing protein 59 
OS=Homo sapiens GN=LRRC59 PE=1 
SV=1 34.9 236.1 6 25.7 0.93 
K2C1_HUMAN 
Keratin, type II cytoskeletal 1 OS=Homo 
sapiens GN=KRT1 PE=1 SV=6 66 202.7 5 5.9 0.93 
HNRPD_HUMAN 
Heterogeneous nuclear ribonucleoprotein 
D0 OS=Homo sapiens GN=HNRNPD 
PE=1 SV=1 38.4 168.2 6 20 0.93 
ALDOA_HUMAN 
Fructose-bisphosphate aldolase A 
OS=Homo sapiens GN=ALDOA PE=1 
SV=2 39.4 402.6 9 31.6 0.93 
HNRPU_HUMAN 
Heterogeneous nuclear ribonucleoprotein U 
OS=Homo sapiens GN=HNRNPU PE=1 
SV=6 90.5 398.3 13 20.4 0.93 
ENOA_HUMAN 
Alpha-enolase OS=Homo sapiens 
GN=ENO1 PE=1 SV=2 47.1 1274.7 26 64.5 0.93 
NCPR_HUMAN 
NADPH--cytochrome P450 reductase 
OS=Homo sapiens GN=POR PE=1 SV=2 76.6 146.1 5 13.3 0.93 
ADT2_HUMAN 
ADP/ATP translocase 2 OS=Homo sapiens 
GN=SLC25A5 PE=1 SV=7 32.8 422.1 13 35.2 0.93 
KAD3_HUMAN GTP:AMP phosphotransferase AK3, 25.5 61 2 11 0.93 
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mitochondrial OS=Homo sapiens 
GN=AK3 PE=1 SV=4 
ODPB_HUMAN 
Pyruvate dehydrogenase E1 component 
subunit beta, mitochondrial OS=Homo 
sapiens GN=PDHB PE=1 SV=3 39.2 56.4 2 8.9 0.93 
TCPE_HUMAN 
T-complex protein 1 subunit epsilon 
OS=Homo sapiens GN=CCT5 PE=1 SV=1 59.6 162 7 15.3 0.93 
NDUA9_HUMAN 
NADH dehydrogenase [ubiquinone] 1 
alpha subcomplex subunit 9, mitochondrial 
OS=Homo sapiens GN=NDUFA9 PE=1 
SV=2 42.5 115.1 4 17.2 0.92 
ECHM_HUMAN 
Enoyl-CoA hydratase, mitochondrial 
OS=Homo sapiens GN=ECHS1 PE=1 
SV=4 31.4 73.5 2 13.1 0.92 
NDUA4_HUMAN 
Cytochrome c oxidase subunit NDUFA4 
OS=Homo sapiens GN=NDUFA4 PE=1 
SV=1 9.4 33.3 1 14.8 0.92 
CTND1_HUMAN 
Catenin delta-1 OS=Homo sapiens 
GN=CTNND1 PE=1 SV=1 108.1 119.5 2 2.9 0.92 
TBA1A_HUMAN 
Tubulin alpha-1A chain OS=Homo sapiens 
GN=TUBA1A PE=1 SV=1 50.1 809.6 17 45.5 0.92 
CATD_HUMAN 
Cathepsin D OS=Homo sapiens 
GN=CTSD PE=1 SV=1 44.5 149.3 6 22.1 0.92 
RS3_HUMAN 
40S ribosomal protein S3 OS=Homo 
sapiens GN=RPS3 PE=1 SV=2 26.7 102.3 4 17.3 0.92 
S12A2_HUMAN 
Solute carrier family 12 member 2 
OS=Homo sapiens GN=SLC12A2 PE=1 
SV=1 131.4 73 3 3.5 0.92 
4F2_HUMAN 
4F2 cell-surface antigen heavy chain 
OS=Homo sapiens GN=SLC3A2 PE=1 
SV=3 68 457.4 12 25.4 0.92 
ACTN4_HUMAN 
Alpha-actinin-4 OS=Homo sapiens 
GN=ACTN4 PE=1 SV=2 104.8 798.1 25 33.9 0.92 
RLA0_HUMAN 
60S acidic ribosomal protein P0 OS=Homo 
sapiens GN=RPLP0 PE=1 SV=1 34.3 281.4 10 48.3 0.92 
SQRD_HUMAN 
Sulfide:quinone oxidoreductase, 
mitochondrial OS=Homo sapiens 
GN=SQRDL PE=1 SV=1 49.9 96.7 4 9.1 0.92 
FAS_HUMAN 
Fatty acid synthase OS=Homo sapiens 
GN=FASN PE=1 SV=3 273.3 469.1 18 8.6 0.92 
QCR1_HUMAN 
Cytochrome b-c1 complex subunit 1, 
mitochondrial OS=Homo sapiens 
GN=UQCRC1 PE=1 SV=3 52.6 137.6 5 16.7 0.92 
COPG2_HUMAN 
Coatomer subunit gamma-2 OS=Homo 
sapiens GN=COPG2 PE=1 SV=1 97.6 36.9 1 1.4 0.92 
IF4A1_HUMAN 
Eukaryotic initiation factor 4A-I 
OS=Homo sapiens GN=EIF4A1 PE=1 
SV=1 46.1 223 7 17.7 0.91 
K2C7_HUMAN 
Keratin, type II cytoskeletal 7 OS=Homo 
sapiens GN=KRT7 PE=1 SV=5 51.4 940.1 24 49.5 0.91 
GCN1_HUMAN 
eIF-2-alpha kinase activator GCN1 
OS=Homo sapiens GN=GCN1 PE=1 SV=6 292.6 128.2 4 3 0.91 
LAMP1_HUMAN 
Lysosome-associated membrane 
glycoprotein 1 OS=Homo sapiens 
GN=LAMP1 PE=1 SV=3 44.9 34.5 1 2.2 0.90 
ETFA_HUMAN 
Electron transfer flavoprotein subunit 
alpha, mitochondrial OS=Homo sapiens 
GN=ETFA PE=1 SV=1 35.1 235.8 5 20.7 0.90 
PGAM2_HUMAN 
Phosphoglycerate mutase 2 OS=Homo 
sapiens GN=PGAM2 PE=1 SV=3 28.7 48.8 1 5.5 0.90 
TCPH_HUMAN 
T-complex protein 1 subunit eta OS=Homo 
sapiens GN=CCT7 PE=1 SV=2 59.3 96.8 3 7.2 0.90 
MCM7_HUMAN 
DNA replication licensing factor MCM7 
OS=Homo sapiens GN=MCM7 PE=1 
SV=4 81.3 67 2 4 0.90 
YBOX1_HUMAN Nuclease-sensitive element-binding protein 35.9 85.6 2 11.1 0.90 
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1 OS=Homo sapiens GN=YBX1 PE=1 
SV=3 
RS20_HUMAN 
40S ribosomal protein S20 OS=Homo 
sapiens GN=RPS20 PE=1 SV=1 13.4 135.7 4 42 0.90 
UBA1_HUMAN 
Ubiquitin-like modifier-activating enzyme 
1 OS=Homo sapiens GN=UBA1 PE=1 
SV=3 117.8 150.2 4 6.1 0.90 
TALDO_HUMAN 
Transaldolase OS=Homo sapiens 
GN=TALDO1 PE=1 SV=2 37.5 164.1 4 13.1 0.90 
TCP4_HUMAN 
Activated RNA polymerase II 
transcriptional coactivator p15 OS=Homo 
sapiens GN=SUB1 PE=1 SV=3 14.4 79.3 2 18.9 0.90 
EZRI_HUMAN 
Ezrin OS=Homo sapiens GN=EZR PE=1 
SV=4 69.4 135.9 5 10.4 0.90 
NUCL_HUMAN 
Nucleolin OS=Homo sapiens GN=NCL 
PE=1 SV=3 76.6 451.4 15 20.1 0.89 
CATB_HUMAN 
Cathepsin B OS=Homo sapiens GN=CTSB 
PE=1 SV=3 37.8 121.1 3 10.3 0.89 
TPM1_HUMAN 
Tropomyosin alpha-1 chain OS=Homo 
sapiens GN=TPM1 PE=1 SV=2 32.7 89.8 2 7 0.89 
K1C18_HUMAN 
Keratin, type I cytoskeletal 18 OS=Homo 
sapiens GN=KRT18 PE=1 SV=2 48 1784.1 40 72.6 0.89 
SYEP_HUMAN 
Bifunctional glutamate/proline--tRNA 
ligase OS=Homo sapiens GN=EPRS PE=1 
SV=5 170.5 84.9 3 2.5 0.88 
KTN1_HUMAN 
Kinectin OS=Homo sapiens GN=KTN1 
PE=1 SV=1 156.2 136.1 4 4.9 0.88 
MOES_HUMAN 
Moesin OS=Homo sapiens GN=MSN 
PE=1 SV=3 67.8 135.6 4 8.3 0.88 
GBLP_HUMAN 
Guanine nucleotide-binding protein subunit 
beta-2-like 1 OS=Homo sapiens 
GN=GNB2L1 PE=1 SV=3 35.1 99.3 4 15.1 0.88 
S10AB_HUMAN 
Protein S100-A11 OS=Homo sapiens 
GN=S100A11 PE=1 SV=2 11.7 94.8 3 34.3 0.87 
K2C8_HUMAN 
Keratin, type II cytoskeletal 8 OS=Homo 
sapiens GN=KRT8 PE=1 SV=7 53.7 2083.5 44 70.4 0.87 
EMC3_HUMAN 
ER membrane protein complex subunit 3 
OS=Homo sapiens GN=EMC3 PE=1 
SV=3 29.9 38.6 1 5.4 0.87 
DHE3_HUMAN 
Glutamate dehydrogenase 1, mitochondrial 
OS=Homo sapiens GN=GLUD1 PE=1 
SV=2 61.4 139.5 5 11.8 0.87 
MYOF_HUMAN 
Myoferlin OS=Homo sapiens GN=MYOF 
PE=1 SV=1 234.6 77.1 3 1.8 0.86 
RS4X_HUMAN 
40S ribosomal protein S4, X isoform 
OS=Homo sapiens GN=RPS4X PE=1 
SV=2 29.6 180.7 7 26.2 0.86 
OLA1_HUMAN 
Obg-like ATPase 1 OS=Homo sapiens 
GN=OLA1 PE=1 SV=2 44.7 39.6 1 3.8 0.86 
DHB4_HUMAN 
Peroxisomal multifunctional enzyme type 2 
OS=Homo sapiens GN=HSD17B4 PE=1 
SV=3 79.6 35.8 1 2 0.86 
FUBP2_HUMAN 
Far upstream element-binding protein 2 
OS=Homo sapiens GN=KHSRP PE=1 
SV=4 73.1 91.1 3 4.5 0.86 
TMEDA_HUMAN 
Transmembrane emp24 domain-containing 
protein 10 OS=Homo sapiens 
GN=TMED10 PE=1 SV=2 25 118.7 4 26.5 0.86 
CMC2_HUMAN 
Calcium-binding mitochondrial carrier 
protein Aralar2 OS=Homo sapiens 
GN=SLC25A13 PE=1 SV=2 74.1 72.1 3 5.8 0.86 
PAIRB_HUMAN 
Plasminogen activator inhibitor 1 RNA-
binding protein OS=Homo sapiens 
GN=SERBP1 PE=1 SV=2 44.9 106.6 3 12 0.86 
IMB1_HUMAN 
Importin subunit beta-1 OS=Homo sapiens 
GN=KPNB1 PE=1 SV=2 97.1 149.1 5 7.4 0.85 
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DYHC1_HUMAN 
Cytoplasmic dynein 1 heavy chain 1 
OS=Homo sapiens GN=DYNC1H1 PE=1 
SV=5 532.1 179.1 7 2 0.85 
SYAC_HUMAN 
Alanine--tRNA ligase, cytoplasmic 
OS=Homo sapiens GN=AARS PE=1 
SV=2 106.7 89.4 3 5 0.85 
SPRE_HUMAN 
Sepiapterin reductase OS=Homo sapiens 
GN=SPR PE=1 SV=1 28 39.7 1 7.3 0.85 
SON_HUMAN 
Protein SON OS=Homo sapiens GN=SON 
PE=1 SV=4 263.7 39.5 1 0.6 0.85 
CBR1_HUMAN 
Carbonyl reductase [NADPH] 1 OS=Homo 
sapiens GN=CBR1 PE=1 SV=3 30.4 90 3 13.4 0.84 
XRCC6_HUMAN 
X-ray repair cross-complementing protein 
6 OS=Homo sapiens GN=XRCC6 PE=1 
SV=2 69.8 423.6 12 26.1 0.84 
K1C19_HUMAN 
Keratin, type I cytoskeletal 19 OS=Homo 
sapiens GN=KRT19 PE=1 SV=4 44.1 389.9 11 27.5 0.84 
ECHB_HUMAN 
Trifunctional enzyme subunit beta, 
mitochondrial OS=Homo sapiens 
GN=HADHB PE=1 SV=3 51.3 204 6 13.1 0.84 
SF3B6_HUMAN 
Splicing factor 3B subunit 6 OS=Homo 
sapiens GN=SF3B6 PE=1 SV=1 14.6 33.2 1 11.2 0.84 
RAB14_HUMAN 
Ras-related protein Rab-14 OS=Homo 
sapiens GN=RAB14 PE=1 SV=4 23.9 55.5 2 11.6 0.84 
RS23_HUMAN 
40S ribosomal protein S23 OS=Homo 
sapiens GN=RPS23 PE=1 SV=3 15.8 94.4 3 23.1 0.83 
PPIF_HUMAN 
Peptidyl-prolyl cis-trans isomerase F, 
mitochondrial OS=Homo sapiens 
GN=PPIF PE=1 SV=1 22 39.8 1 4.8 0.83 
CRIP1_HUMAN 
Cysteine-rich protein 1 OS=Homo sapiens 
GN=CRIP1 PE=1 SV=3 8.5 46.1 2 20.8 0.82 
DDX21_HUMAN 
Nucleolar RNA helicase 2 OS=Homo 
sapiens GN=DDX21 PE=1 SV=5 87.3 59.8 2 3.4 0.82 
LPPRC_HUMAN 
Leucine-rich PPR motif-containing protein, 
mitochondrial OS=Homo sapiens 
GN=LRPPRC PE=1 SV=3 157.8 389.6 13 13 0.82 
HACD3_HUMAN 
Very-long-chain (3R)-3-hydroxyacyl-CoA 
dehydratase 3 OS=Homo sapiens 
GN=HACD3 PE=1 SV=2 43.1 34.6 1 3 0.82 
FIS1_HUMAN 
Mitochondrial fission 1 protein OS=Homo 
sapiens GN=FIS1 PE=1 SV=2 16.9 36.1 1 7.2 0.81 
CNPY2_HUMAN 
Protein canopy homolog 2 OS=Homo 
sapiens GN=CNPY2 PE=1 SV=1 20.6 59.5 1 8.8 0.81 
LA_HUMAN 
Lupus La protein OS=Homo sapiens 
GN=SSB PE=1 SV=2 46.8 85 3 9.3 0.81 
PTRF_HUMAN 
Polymerase I and transcript release factor 
OS=Homo sapiens GN=PTRF PE=1 SV=1 43.4 53.5 1 4.6 0.81 
COR1C_HUMAN 
Coronin-1C OS=Homo sapiens 
GN=CORO1C PE=1 SV=1 53.2 51.8 1 3.4 0.81 
TIM50_HUMAN 
Mitochondrial import inner membrane 
translocase subunit TIM50 OS=Homo 
sapiens GN=TIMM50 PE=1 SV=2 39.6 55.4 2 7.6 0.81 
ACSL3_HUMAN 
Long-chain-fatty-acid--CoA ligase 3 
OS=Homo sapiens GN=ACSL3 PE=1 
SV=3 80.4 103.3 4 7.5 0.79 
RL11_HUMAN 
60S ribosomal protein L11 OS=Homo 
sapiens GN=RPL11 PE=1 SV=2 20.2 36 1 7.9 0.79 
CAH12_HUMAN 
Carbonic anhydrase 12 OS=Homo sapiens 
GN=CA12 PE=1 SV=1 39.4 85.4 2 13 0.79 
EIF3E_HUMAN 
Eukaryotic translation initiation factor 3 
subunit E OS=Homo sapiens GN=EIF3E 
PE=1 SV=1 52.2 44.2 1 2.9 0.78 
K1C10_HUMAN 
Keratin, type I cytoskeletal 10 OS=Homo 
sapiens GN=KRT10 PE=1 SV=6 58.8 140.3 5 9.4 0.78 
UGGG1_HUMAN 
UDP-glucose:glycoprotein 
glucosyltransferase 1 OS=Homo sapiens 177.1 37.3 1 0.9 0.77 
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GN=UGGT1 PE=1 SV=3 
VAPB_HUMAN 
Vesicle-associated membrane protein-
associated protein B/C OS=Homo sapiens 
GN=VAPB PE=1 SV=3 27.2 34.9 1 5.8 0.75 
SC22B_HUMAN 
Vesicle-trafficking protein SEC22b 
OS=Homo sapiens GN=SEC22B PE=1 
SV=4 24.6 38.1 1 5.6 0.74 
PTGES_HUMAN 
Prostaglandin E synthase OS=Homo 
sapiens GN=PTGES PE=1 SV=2 17.1 43.1 1 6.6 0.72 
DIC_HUMAN 
Mitochondrial dicarboxylate carrier 
OS=Homo sapiens GN=SLC25A10 PE=1 
SV=2 31.3 39.6 1 8.4 0.72 
UBQL1_HUMAN 
Ubiquilin-1 OS=Homo sapiens 
GN=UBQLN1 PE=1 SV=2 62.5 69.6 2 5.9 0.71 
SF3B1_HUMAN 
Splicing factor 3B subunit 1 OS=Homo 
sapiens GN=SF3B1 PE=1 SV=3 145.7 64.9 2 3.4 0.70 
PSB6_HUMAN 
Proteasome subunit beta type-6 OS=Homo 
sapiens GN=PSMB6 PE=1 SV=4 25.3 34.1 1 3.8 0.70 
ITA3_HUMAN 
Integrin alpha-3 OS=Homo sapiens 
GN=ITGA3 PE=1 SV=5 116.5 81.6 2 2.6 0.69 
ESYT1_HUMAN 
Extended synaptotagmin-1 OS=Homo 
sapiens GN=ESYT1 PE=1 SV=1 122.8 83.2 3 3.6 0.68 
GLSK_HUMAN 
Glutaminase kidney isoform, mitochondrial 
OS=Homo sapiens GN=GLS PE=1 SV=1 73.4 31.4 1 2.5 0.67 
PSMD1_HUMAN 
26S proteasome non-ATPase regulatory 
subunit 1 OS=Homo sapiens GN=PSMD1 
PE=1 SV=2 105.8 50.5 2 4 0.65 
DDX42_HUMAN 
ATP-dependent RNA helicase DDX42 
OS=Homo sapiens GN=DDX42 PE=1 
SV=1 102.9 33.5 1 1.4 0.65 
TGM2_HUMAN 
Protein-glutamine gamma-
glutamyltransferase 2 OS=Homo sapiens 
GN=TGM2 PE=1 SV=2 77.3 68.7 2 4.2 0.65 
AT1A2_HUMAN 
Sodium/potassium-transporting ATPase 
subunit alpha-2 OS=Homo sapiens 
GN=ATP1A2 PE=1 SV=1 112.2 88.9 1 1.8 0.64 
ROA0_HUMAN 
Heterogeneous nuclear ribonucleoprotein 
A0 OS=Homo sapiens GN=HNRNPA0 
PE=1 SV=1 30.8 67.6 2 7.5 0.62 
TOP2B_HUMAN 
DNA topoisomerase 2-beta OS=Homo 
sapiens GN=TOP2B PE=1 SV=3 183.2 34.9 1 0.7 0.61 
PRS10_HUMAN 
26S protease regulatory subunit 10B 
OS=Homo sapiens GN=PSMC6 PE=1 
SV=1 44.1 101.8 3 10.8 0.60 
TPD52_HUMAN 
Tumor protein D52 OS=Homo sapiens 
GN=TPD52 PE=1 SV=2 24.3 37.7 1 6.7 0.59 
THOC4_HUMAN 
THO complex subunit 4 OS=Homo sapiens 
GN=ALYREF PE=1 SV=3 26.9 71.9 3 15.2 0.58 
DEST_HUMAN 
Destrin OS=Homo sapiens GN=DSTN 
PE=1 SV=3 18.5 37 1 8.5 0.56 
NAA15_HUMAN 
N-alpha-acetyltransferase 15, NatA 
auxiliary subunit OS=Homo sapiens 
GN=NAA15 PE=1 SV=1 101.2 36.6 1 1.7 0.53 
RSMB_HUMAN 
Small nuclear ribonucleoprotein-associated 
proteins B and B' OS=Homo sapiens 
GN=SNRPB PE=1 SV=2 24.6 27.3 1 3.3 0.52 
MYADM_HUMAN 
Myeloid-associated differentiation marker 
OS=Homo sapiens GN=MYADM PE=1 
SV=2 35.3 60.7 1 7.1 0.44 
 
1 
UniProtKB accession numbers; 
2 
Molecular weight; 
3 
Mascot score; 
4
 Number of identified peptides; 
5
 Sequence coverage; 
6
 Median of the measured iTRAQ ratios. 
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